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ABSTRACT
High dimensional data are more common nowadays, because the collection of such
data becomes larger and more complex due to the technology advance of the computer
science, biology, etc. The analysis of high dimensional data is different from tradi-
tional data analysis, and variable selection for high dimensional data becomes very
challenging. Structural equation modeling (SEM) analyzes the relationship between
manifest variables and latent variables. The structural equation focuses on analyzing
the relationship between latent variables. New proposed methods of these topics are
discussed in the dissertation.
In the first chapter, we review the basic concept of survival analysis, SEM, and
current method of variable selection in those two scenarios. We also introduce the
available software package for current methods and relevant data set.
In the second chapter, we develop a Bayesian kernel machine model with incorpo-
rating existing information on pathways and gene networks in the analysis of DNA
microarray data. Each pathway is modeled nonparametrically using reproducing ker-
nel Hilbert space. The pathways and the genes are selected via assigning mixture
priors on the pathway indicator variable and the gene indicator variable. This ap-
proach helped us in flexible modeling of the pathway effects, which can capture both
linear and non-linear effect. Moreover, the model can also pinpoint the important
pathways and the important active genes within each pathway. We have also devel-
oped an efficient Markov Chain Monte Carlo (MCMC) algorithm to fit our model.
We used simulations and a real data analysis, [van ’t Veer et al., 2002] breast cancer
microarray data, to illustrate the proposed method.
xii
In the third chapter, we extend the idea of semiparametric structural equation
model where the nonlinear functional relationships are approximated using basis ex-
pansions [Guo et al., 2012]. Many basis expansion methods, including cubic splines,
are known to induce correlations. In this chapter we compare standard Lasso, Fused
Lasso and Elastic Net to account for correlations in both the covariate and basis
expansions. To illustrate the usefulness of the proposed methods, a simulation study
and a real data study have been performed. The semiparametric structural equa-
tion models based on Bayesian fused Lasso and Bayesian elastic-net outperform the
Bayesian Lasso model.
In the fourth chapter, we apply Bayesian Graph Laplacian Model, developed by
[Liu et al., 2014] and generalized the graph Laplacian allowing both positively and
negatively correlated variable, to analyze gene expression data from Michigan prostate
cancer study [Dhanasekaran et al., 2001]. We find out the underlie gene network and
interaction related to prostate cancer and discuss the possible extensions for Bayesian
Graph Laplacian Model, including analyzing multiple pathways simultaneously and
pathways selection, right censored data as response variable and binomial or multi-
nomial data as response variable.
xiii
Chapter 1
Introduction
Survival analysis focus on analyzing time to events such as death, disease occurrence,
and malfunction in mechanical system. The event can be referred to as the failure.
Suppose we analyze the data consisting of time to the occurrence of certain type
of cancer. It is possible that some of the patients have no occurrence at the end of
the study. As a result, the exact failure times of such patients are unknown, but they
are only unknown to be greater than certain amount of time. This feature is referred
to as censoring in survival analysis.
The gene expression microarray data contain the information for thousands of
genes. Oncologist have been trying to identify genes related to different cancers.
Using microarray data and survival time for the patients to identify important genes
presents a challenge in data analysis. This chapter contains a literature review on the
analysis of right-censored survival data and the variable selection in high dimensional
situation.
In psychology, latent variables represent the variables which cannot be measured
1
directly. Structural Equation Modeling (SEM) analyzes the relationship between
latent variables and manifest variables. In this chapter, we present a literature review
on SEM.
We review general concept of survival analysis and survival models under frequen-
tist perspective in section 1.1; in section 1.2, we review parametric and semiparametric
Bayesian model analyzing survival data; section 1.3 covers the current methods on
variable selection in high dimensional data and discusses the difficulties and challenges
of the current methods; we introduce the concept of genetic pathway in section 1.4;
section 1.5 contains the introduction for Structural equation modeling; we discuss the
motivation and outline of this thesis in section 1.6; and section 1.7 lists the available
software package and relevant data set.
1.1 Survival Analysis Under Frequentist Perspec-
tive
Let T be a non-negative continuous random variable denoting the failure time of a
subject. The probability of a subject surviving beyond a specific time t is given by
the survival function, defined as
S(t) = P (T > t), (1.1)
where S(t) is a monotonically decreasing, right-continuous, S(0) = 1 and limt→∞ S(t) =
0 function.
The hazard function, λ(t), is the instantaneous rate at which failures occur given
2
the condition that subjects survive at the time t or later. It is defined as
λ(t) = lim
∆t→0
P (t ≤ T < t+ ∆t|T ≥ t)
∆t
. (1.2)
The probability density function of T is f(t) = −dS(t)/dt, where t ∈ [0,+∞),
therefore (1.2) follows that
λ(t) = f(t)/S(t) = −d logS(t)/dt. (1.3)
Given S(0) = 1, by integrating t from both sides of (1.3) we get
S(t) = exp{−
∫ t
0
λ(s)ds} = exp{−Λ(t)}, (1.4)
whereΛ(t) is called cumulative hazard function and Λ(t) =
∫ t
0
λ(s)ds. Taking deriva-
tive with respect to t in (1.4), we obtain
s(t) = λ(t) exp{−Λ(t)}. (1.5)
We use log logistic probability density function to illustrate the survival function and
responding hazard function in figure (1.1).
One special feature of the survival data is known as censoring. Because of the time
limit, cost concern or incidence related to experimental subjects, the investigators
terminate the research before all subjects realize their event of interest or some of the
subjects leave the research before research ends. As a result, survival times from some
of the subjects are longer than some certain values. It is called right censored when
the survival time of a subject exceeds certain censoring time, Cr, and left censored
3
(a) Survival function (b) Hazard function
Figure 1.1: An example of hazard function and survival function
when the survival time is only know to be less than a censoring time, Cl. Interval
censoring occurs when the precise survival time is unknown, but it is within a known
interval, (Cl,Cr).
1.1.1 Proportional Hazards Regression
Proportional hazards Regression model is one of the regression models for survival
data. According to [Cox, 1972], for a subject with covariate vector x = (x1, x2, · · · , xp)′,
the hazard rate at time t can be expressed as:
λ(t|x) = λ0(t)exp(x′β), (1.6)
where β = (β1, β2, · · · , βp)′ is a p×1 vector of regression parameters corresponding to
x, and λ0(·) is an arbitrary unknown baseline hazard function. With fixed covariate,
the ratio of hazards between each subject is constant over time.
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The survival function (1.4) corresponding to (1.6) is
S(t|x) = exp{− exp(x′β)
∫ t
0
λ0(µ)dµ}, (1.7)
and the density function of T corresponding to (1.6) is
f(t|x) = λ0(t)exp(x′β) exp{− exp(x′β)
∫ t
0
λ0(µ)dµ}. (1.8)
There are two important extension of the proportional hazards regression model:
(i) stratified Cox model and (ii) time-dependent covariate model. In stratified Cox
model, if λ0(·) is arbitrary and there are J strata in the population, the hazard
function for jth stratum is
λj(t|x) = λ0j(t) exp(x′β), (1.9)
for j = 1, · · · , J , where λ0j(t) is the corresponding baseline hazard function for the
jth stratum.
When the covariates are time-dependent. Cox model can be easily extended to
time-variant covariates:
λ(t|x(t)) = λ0(t)exp(x(t)′β). (1.10)
When n > p and only one subject fails at each time, maximizing the partial
5
likelihood is used to find the estimate of β [Cox, 1975],
L(β) =
∏
k∈D
exp(x′kβ)∑
l∈Rk exp(x
′
lβ)
, (1.11)
where D is the set of indicators of failure times and Rk is the set of indicator of
subjects at risk right before tk. If there are ties, we use the approximation [Breslow
and Crowley, 1974] or [Efron, 1977] to the partial likelihood (1.11).
1.1.2 Accelerated Failure Time Models
In the hazard function (1.6), the multiplicative effect of the covariate has a clear
meaning, but because of unknown baseline hazard function λ0(·), there is no direction
relationship between covariate x and the survival time T . Suppose a linear model
Y = x′β+ θ, where Y = log(T ) and  is an error variable with some density function.
The model can be written as T = exp(x′β)V , where V = exp(θ) has hazard function
λ0(v). Then the hazard function for T with covariates x can be written as
λ(t|x) = exp(−x′β)λ0{t exp(−x′β)}. (1.12)
In (1.12), it is obvious that the effect of covariates in the model is multiplicative
on t. When x = 0, there is a baseline hazard function λ0(t); when x 6= 0, the
covariates of each subject affects the hazard rate along with t. The role of covariate is
to accelerate (or decelerate) the time to failure. The corresponding survivor function
6
is
S(t|x) = exp{−
∫ t
0
exp(−x′β)λ0(µe−x′β)dµ}
= exp{−Λ0(te−x′β)},
where Λ0(t) =
∫ t
0
λ0(µ)dµ.
The extensions of the model include stratifying the model and incorporating time-
dependent covariates.
1.2 Survival Analysis under the Bayesian Perspec-
tive
1.2.1 Parametric Models
Parametric modeling is straightforward, and many Bayesian analyses in practice are
based on a parametric model. In this section, we cover the Weibull model, one of the
most widely used parametric survival model.
Suppose we have survival times t = (t1, t2, · · · , tn)′, each independent and identi-
cally following Weibull distribution, W(α, λ), as
f(ti|α, λ) = αtα−1i exp(λ− exp(λ)tαi ), (1.13)
where i = 1, · · · , n. The corresponding survival function is S(ti|α, λ) = exp(− exp(λ)tαi ).
The censoring indicator is given as δ = (δ1, δ2, · · · , δn) with δi = 0 when ti is right cen-
sored time and δi = 1. When ti is a known survival time, we can write the likelihood
7
function of (α, λ) as
L(α, λ|n, t, δ) =
n∏
i=1
f(ti|α, λ)δiS(ti|α, λ)1−δi (1.14)
= α
∑n
i=1 δi exp{λ
n∑
i=1
δi +
n∑
i=1
(δi(α− 1) log(ti)− exp(λ)tαi )}.
To form a Weibull regression model, let λi = x
′
iβ, where the covariate xi is a p×1
vector and corresponding regression coefficient parameter β is also a p× 1 vector.
Let Np(µ0,Σ0) to be the normal prior for β and G(α0, κ0) to be the gamma prior
for α, we have the joint posterior as
pi(β, α|n, t,delta) ∝ α
∑n
i=1 δi+α0−1 exp{
n∑
i=1
(δix
′
iβ + δi(α− 1) log(ti)− tαi exp(x′iβ))(1.15)
−κ0α− (β − µ0)Σ
−1
0 (β − µ0)
2
}
The posterior distribution of β does not have a closed form, so numerical integra-
tion or MCMC methods are used to estimate the posterior distribution of β.
1.2.2 Semiparametric Models
In this section, we consider Bayesian semiparametric approach for the accelerated
failure time model and Bayesian Cox proportional model.
Let data set without censoring, t = (t1, t2, · · · , tn)′ be independently and identi-
cally distributed, X is n×p matrix of covariates with ith row x′i representing a vector
of covariates for subject i, and β is the corresponding coefficient of the covariates.
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From section 1.1.2, the probability model is,
ti = exp(−x′iβ)νi, (1.16)
where νi = exp(θi). A mixture of Dirichlet processes (MDP) is used as a prior for θi
by [Kuo and Mallick, 1997]. Assume νi are independently and identically distributed
with density:
f(νi|G) =
∫
f(νi|ψi)G(dψi), (1.17)
where unknown G is given by a Dirichlet-process prior with known parameters and
f(νi|ψi) is a kernel density with kernel parameter ψi. With (1.2.2) and (1.17), the
likelihood function of Y can be written as,
f(Y |β, G) =
n∏
i=1
exp(x′iβ)
∫
f(yi exp(x
′
iβ)|ψi)G(dψi). (1.18)
Let the prior of β = pi(β), the posterior of β is
β|ψ, Y ∝ pi(β)
n∏
i=1
exp(x′iβ)f(yi exp(x
′
iβ)|ψi). (1.19)
[Kuo and Mallick, 1997] has more details. [Ghosh and Ghosal, 2005] prove the
posterior consistency of semiparametric AFT models with censored data. For the
censored data, data augmentation is used. Let δi = I{ti ≤ ci} be the censoring
indicator and W = (w1, · · · , wn)′, where wi = log(ti), be the augmented data, we
have 
wi = log(t
∗
i ) if δi = 1
wi > log(t
∗
i ) if δi = 0.
(1.20)
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[Sha et al., 2006] assumes the θ in are iid N(0, σ2), as a result the T ’s are log-
normally distributed. The augmented data follow normal distribution, W |X,β, σ2 ∼
N(Xβ, σ2I), with In×n the identity matrix.
The priors for this model are following,
β ∼ N(β0, σ2Σ0) (1.21)
σ2 ∼ IG(v0/2, v0σ20/2). (1.22)
[Sha et al., 2006] is interested in variable selection rather than estimation of β’s.
The mixture priors for variable selection is
βj|γj, σ2 ∼ (1− γj)I(0) + γjN(0, σ2τj), (1.23)
where τj is the jth diagonal element of σ0. pi(γj) is the prior for γj following in-
dependent Bernoulli distribution. γj = 1 indicates j-th variable is selected in the
model.
After integrating out β and σ2, marginal likelihood of the augmented data is a
multivariate t-distribution,
W |X(γ) ∼ Tv0 [Xβ0, σ0(I +XΣ0X ′)]. (1.24)
Posterior for the γ is,
p(γ|X,W ) ∝
n∏
j=1
p(γj)p(W |X(γ)). (1.25)
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[Sha et al., 2006] also discuss the model with log-t prior for β’s.
The other model is one of the most convenient and popular models for semipara-
metric survival analysis, the Cox proportional hazards model. Instead of assuming
multiplicative effect on the t, cox model assumes a multiplicative effect on the haz-
ard functions. To construct this model, we first consider a finite partition of time,
0 < s1 < s2 < · · · < sK , with sK > ti for all subjects from i = 1, 2, · · · , n. Thus, we
form K intervals, and the k intervals is Ik ∈ (sk−1, sk]. To form a piecewise constant
hazard model, let the baseline hazard λ0(t) = λk for t ∈ Ik and t = (t1, t2, · · · , tn).
The maximum likelihood function is
p(t|β,λ, X, ν, δ) =
n∏
i=1
K∏
k=1
(λj exp(x
′
iβ))
δikνi exp{−δik[λj(ti − sk−1) (1.26)
+
k−1∑
g=1
λg(sg − sg−1)] exp(x′iβ)},
where ν = (ν1, ν2, · · · , νn)′ with νi = 1 if the ith subject has an exact failure time and
0 right censored time, δik = 1 if the i
th subject failed or is censored in the interval Ik.
Prior of the baseline hazard λ follows independent gamma distribution and prior
of β follows independent normal distribution,
pi(λk) ∼ G(α0k, λ0k) (1.27)
pi(βj) ∼ N(0, σ20), (1.28)
where α0k, λ0k and σ
2
0 are known. And the joint posterior distribution of λ and β is,
p(λ,β|t, X, ν, δ) ∝ p(t|β,λ, X, ν, δ)pi(λ)pi(β), (1.29)
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[Sinha et al., 1999] considers discrete hazard model allows for time-dependent regres-
sion coefficients.
1.3 Variable Selection in Gene Expression Data
and Related Difficulties
DNA microarrays measure the expression levels of large numbers of genes simulta-
neously. These measurements, gene expression profiling, can identify between cells
that are actively dividing, or show how the cells react to a treatment. One of the
objectives to analyze gene expression is to link the survival time to certain subset
of genes, pathway or both. The identified genes/pathways in the subset can be used
either to inform biologists to do more research on the related subset or to build a
statistical model to predict the survival time of new patients.
In statistics analysis, one difficulty is the incomplete data due to censoring. The
other difficulty is the number of genes(p) is usually much larger than the number of
experimental subjects(n), because of the nature of gene expression data. Therefore
transitional regression analysis is not useful in this scenario. Supervised principal
components [Bair et al., 2006] which reduces the dimension of the predictor can be
used to solve this difficulty.
Even though p  n, the number of genes related to survival time is usually
very small comparing to p. To encourage the sparsity of the coefficients and model
selection in the same time, [Tibshirani, 1996] introduced the least absolute shrinkage
and selection operator (Lasso) penalty based on the L1-norm. The lasso method
makes some coefficient exactly equal to 0 and hence the genes related to survival time
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can be identified. [Tibshirani, 1997] extend the Lasso method to Cox proportional
model. [Gui and Li, 2005] applies least-angle regression (LARS) method to Cox
model. LARS-COX procedure reduce the computational difficulty of Lasso Method
based on the L1-norm in the Cox Model. However, all the methods above can only
select at most n genes. If the n is relatively very small, this limitation would cause a
problem. Bayesian framework can handle this limitation.
Bayesian framework can solve the limitation we mentioned above. Variable selec-
tion under the Bayesian framework traditionally has been done by the SSVS(Stochastic
Search Variable Selection) procedure [George and McCulloch, 2005]. The predictors
that have higher posterior probability can form a promising subset in this procedure.
[E. et al., 2003] and [Tibshirani et al., 2005b] extend the SSVS procedure to discrete
response models. [Tanner and Wong, 1987] introduce data augmentation by calcu-
lating the posterior distribution of missing data. This approach is widely used to
impute the censored data in survival analysis. [Sha et al., 2006] consider accelerated
failure time (AFT) models to select important genes with augmented survival data
assuming the survival time follows log-normal or log-t distribution. Bayesian gene
selection applies in non-linear binary and multiclass problems by [Chakraborty et al.,
2007] and [Chakraborty, 2009]
1.3.1 Supervised Principal Components Regression
[Bair et al., 2006] propsed supervised principal components regression (SPC) by
adapting ideas of dimension reduction and penalized regression. The idea of SPC
is to compute univariate standard regression coefficients for each predictor and only
keep the predictors whose absolute value of univariate coefficient exceeds a threshold
13
θ. The remained predictors form a reduced matrix. Then we compute the first (or
first few) principal component of the reduce matrix and use them to predict the re-
sponse variable. SPC has a consistent estimation for regression coefficient parameters
as n and p→∞, but the usual principal components regression does not.
1.3.2 Cox Univariate Shrinkage Method
[Tibshirani, 2009] proposed Cox univariate shrinkage (CUS) estimator, which finds
estimate using a set of simple one-dimensional maximization with the Lasso penalty
under the assumption that the features are independent. Under this assumption, the
partial likelihood (1.11) can be written as following:
L(β) ∝
p∏
j−1
∏
k∈D
exp(xkjβj)∑
m∈Rk exp(xmjβj)
(1.30)
The log partial likelihood is
l(β) ∝
p∑
j=1
K∑
k=1
(xkjβj − log
∑
m∈Rk
exp(xmjβj)) (1.31)
where K represent the total number of different failure times. The proposed CUS
estimator is as the maximizer of the penalized partial log-likelhood,
J(β) =
p∑
j=1
gj(βj)− λ
∑
|βj| (1.32)
where gj(β) ≡
∑K
k=1(xkjβj− log
∑
m∈Rk exp(xmjβj)) and λ ≥ 0 is the tuning parame-
ter. The problem can be solved for a range of λ values and it is a set of one-dimensional
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maximizations, because each function gj(βj) − λ
∑ |βj| in (1.32) can be maximized
separately.
1.3.3 Iterative Bayesian Model Average
To Analyze survival data with microarray predictors, [Annest et al., 2009] developed
the iterative Bayesian Model Average (BMA) algorithm. In this algorithm, the par-
tial log likelihood of each genomic variable is calculated and the top 25 geneomic
variables with a largest log likelihood value are chosen in the initial model. After ap-
plying iterative BMA algorithm, the 25 genes which have low posterior probabilities,
generally the threshold is 1%, would be removed from the initial model. Suppose we
have k number of genes removed from the initial model, then k genes with highest
log likelihood value next to the initial 25 genes would be selected in the model. The
process continues until all the genes have been considered. The traditional BMA
algorithm includes the leaps and bounds algorithm and it is not efficient when the
number of predictors is greater than 30, so only 25 genes are considered at each it-
eration. As a result, iterative BMA cannot selected more than 25 genes in our case,
more generally, more than the size of the BMA window (maximum 30).
1.3.4 Bayesian Variable Selection in AFT Model
Based on variable selection in regression and multinomial probit models [Sha et al.,
2004], [Sha et al., 2006] extended this Bayesian variable selection approach to accel-
erated failure time (AFT) models. The censored survival times are imputed using a
data augmentation approach proposed by [Tanner and Wong, 1987] with log-normal
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or log-t distributional assumptions. The full conditional of a censored case follows a
univariate truncated t-distribution and it can be updated using Gibbs sampling. The
regression coefficients are assumed to arise from a scale mixture of a point mass at
0 and a normal density [George and McCulloch, 2005] by adding a latent vector, γ,
with Bernoulli distribution to the prior of coefficients. The joint posterior distribution
of γ or the marginal posterior distributions of its elements can be used to make the
variable selection. We discuss the model on detail in section(1.2.2).
There are some major limitations for microarray data analysis when only one gene
is considered individually, because cellular processes often affect sets of genes instead
of one, and the biological mechanisms are more related to moderate changes in several
genes than dramatic change in a single gene [Mootha et al., 2003]. [Liu et al., 2007]
consider a semiparametric regression model with covariates and a genetic pathway.
The covariates are modeled parametrically and the genes in the pathway are modeled
using least-squares kernel machines (LSKMS). The overall effect of the pathway can
be tested in the semiparametric model.
[Stingo et al., 2011] considers the selection of pathways and genes simultaneously
with biological information, which includes the membership of genes in pathways
and the relationships between genes, Kyoto Encyclopedia of Genes and Genomes
(KEGG)[Kanehisa and Goto, 2000].
[Stingo et al., 2011] apply PLS regression of Y on a subset of selected genes and
pathways,
Y = 1α +
Kθ∑
k=1
Tk(γ)βk(γ) + , (1.33)
where θ is the indicator of selected pathways, Kθ =
∑K
k=1 θk is the number of selected
pathways, γ is the indicator of selected genes, γ Tk(γ) is the first latent PLS component
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from microarray data of selected pathway k and corresponding selected genes, and
 ∼ N(0, σ2). The model can be also written as,
Y |X, α,β, σ2 ∼ N(1α +
Kθ∑
k=1
Tk(γ)βk(γ), σ
2I). (1.34)
Priors for regression parameters are,
βk|θk, σ2 ∼ θkN(β0, hσ2) + (1− θk)δ0(βk) (1.35)
α|σ2 ∼ N(α0, h0σ2) (1.36)
σ2 ∼ IG(v0/2, v0σ20/2), (1.37)
where α0, β0, h0, h, v0 and σ
2
0 are known.
Priors for pathway and gene selection indicator are,
p(θ,γ|µ, η) ∝
K∏
k=1
ψθkk (1− ψk)1−θk exp(µ1′γ + ηγ ′Rγ), (1.38)
where ψk, µ, and η are known. R is the gene relationship matrix.
By multiplying the prior of α, β and σ2 to (1.34) and then integrating out them,
we get a multivariate t-distribution,
f(Y |T ,θ,γ) ∼ Tv0(α01 + Tθ,γβ0, σ20(I = h011′ + Tθ,γΣ0T ′θ,γ)). (1.39)
And the joint posterior distribution of the pathway and gene selection indicators is
f(θ,γ, η|T , Y ) ∝ f(Y |T ,θ,γ)p(θ,γ|µ, η). (1.40)
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Pathways and genes are selected by three moves: adding/removing a pathway and
a gene; adding/removing a gene; adding/removing a pathway.
1.4 Genetic pathways
A genetic pathway figure(1.2) is the set of interactions occurring between a group
of genes. The interactions together execute certain biological function(s). As we
mention before, biological mechanisms are more related to moderate changes in several
genes than dramatic change in a single gene. Studying pathway makes us better
understanding biological mechanisms. It is possible that more than one pathway
related to a certain disease, and finding those related pathways will help us learn
more about disease process figure(1.3).
1.5 Structural Equation Modeling
Structural Equation Modeling can be used where the data set contain manifest(observed)
and latent(unobserved) variables. Manifest variables can be measured directly, while
latent variables cannot.
1.5.1 Introduction
Exploratory factor analysis (EFA) is a basic SEM, and it is defined as follow:
y = Λω +  (1.41)
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Figure 1.2: Steroid hormone biosynthesis pathway
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Figure 1.3: Schematic representation of the relationship among genes, pathways and
diseases [Stingo et al., 2011]
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where Λ is a p× q unknown parameter matrix (factor loadings), ω is a q×1 vector of
latent variables,  is a p× 1 vector of measurement errors. ω and  are independent.
ω follows a N [0, I] distribution and  follows normal distribution as N [0,Ψ], where
Ψ is a diagonal matrix. The observable response variables y follows a N [0,Σ], where
Σ = ΛΛT + Ψ.
The latent variables are correlated with each other, which means  follows a
N [0,Φ] and Φ is a positive definite covariance, so that the previous model becomes
the confirmatory factor analysis (CFA) model, which is a natural extension of the
EFA model. And Σ = ΛΦΛT + Ψ
(1.41) is refereed to be measurement equation, which represent the relationship
between Manifest variables and latent variable. In a general structural equation
model, the relationship among latent variables is also considered. If SEMs assume
linear relations among latent variables [Jo˝reskog, 1973], the full structural model is
defined as follows:
η = Πη + Γξ + ζ, (1.42)
where η is a q1 × 1 vector of endogenous latent variables and ξ is a q2 × 1 vector of
exogenous latent variables, Π is a q1 × q1 unknown matrix of regression coefficients
relating the latent endogenous variables to each other and Γ is a q2 × q2 unknown
matrix of regression coefficients relating the exogenous latent variables to the en-
dogenous latent variables. In this case, ω can be defined as ω = (ηT , ξT )T , so the
measurement equation for the general structure equation model is still (1.41).
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1.5.2 Bayesian Estimation
To illustrate the Bayesian method, let us consider CFA model. Suppose there are n
observations and i = 1, · · · , n, so (1.41) becomes:
yi = Λωi + i. (1.43)
Priors
Let Λk be the kth column of Λ and kth diagonal elements of Ψ be ψk, conjugate
priors for Λk and ψk are,
Λk|ψk ∼ N(Λ0k, ψkH0yk) (1.44)
ψ−1k ∼ Gamma(α0k, β0k), (1.45)
where α0k, β0k, Λ0k and positive definite matrix H0yk are hyperparameters.
For Φ, a conjuage prior is a q dimensional Inverted Wishart distribution:
Φ ∼ IWq(R0, ρ0), (1.46)
where positive definite matrix R0 and ρ are hyperparameters.
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Full conditional distribution
The parameters of interest are θ = (Λ,Ψ,Φ)
T . Let Ω = (ω1, · · · ,ωn) and the
conditional distribution of Ω is:
p(Ω|Y ,β) =
n∏
i=1
p(ωi|yi,θ) ∝
n∏
i=1
p(ωi|θ)p(yi|ωi,θ), (1.47)
where ωi ∼ N(0,Φ) and yi|ωi,θ ∼ N(Λωi,Ψ), so
ωi|yi,θ ∼ N((Φ−1 + ΛTΨ−1 Λ)−1ΛTΨ−1 yi, (Φ−1 + ΛTΨ−1 Λ)−1). (1.48)
For θ, the conditional distributions are:
ψ−1k |Y ,Ω ∼ Gamma(n/2 + α0k, βk) (1.49)
Λk|Y ,Ω, ψ−1k ∼ N(ak, ψkAk) (1.50)
Φ|Y ,Ω ∼ IWq(ΩΩT +R−10 , n+ ρ0), (1.51)
where Ak = (H
−1
0yk + ΩΩ
T )−1 and ak = Ak(H−10ykΛ0k + ΩYk)
The Gibbs sampler can be used to generate the posterior distribution of θ and ω.
1.6 Motivation and Outline of the Study
Much attention has been given recently to the development of methods that utilize
the large quantity of genetic information. Most of the proposed methods look at the
entire set of genes and their impact on a disease. Recently a new philosophy emerged
which considers the genetic pathways, which contain sets of genes, combined effect
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on a disease. Under the new philosophy the goal is to identify the significant genetic
pathways and the corresponding influential genes in regards to different diseases.
In Chapter 2, a Bayesian kernel machine model which incorporates existing in-
formation on pathways and gene networks in the analysis of DNA microarray data
is developed. Each pathway is modeled nonparametrically using a reproducing ker-
nel Hilbert space. Mixture priors on the pathway indicator variable and the gene
indicator variable are assigned. This approach can be used to model both linear and
non-linear pathway effects and can pinpoint the important pathways along with the
active genes within each pathway. An efficient Markov Chain Monte Carlo (MCMC)
algorithm is developed to fit our model. A simulation study and a real data analysis,
using, [van ’t Veer et al., 2002] breast cancer microarray data, are used to illustrate
the proposed method.
In Chapter 3, we focus on Structural equation modeling. Structural equation mod-
els are a well-developed statistical tool for dealing with multivariate data that contain
latent variables. Recently much attention has been given to developing structural
equation models that account for nonlinear relationships between the endogenous la-
tent variable and the covariates and endogenous latent variables. [Guo et al., 2012]
developed a semiparametric structural equation model where the nonlinear functional
relationships were approximated using basis expansions. Many basis expansion meth-
ods, including cubic splines, are known to induce correlations. In this chapter, we
compare standard Lasso, Fused Lasso and Elastic Net to account for correlations in
both the covariate and basis expansions. To illustrate the usefulness of the proposed
method a simulation study has been performed. Results indicate that the Elastic Net
is most efficient at approximating the nonlinear relationships between the endogenous
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latent variable and the covariates and endogenous latent variables.
1.7 Software and Data Sets
1.7.1 Software
The methodologies that we mentioned on 1.3, Supervised Principal Components Re-
gression, Cox Univariate Shrinkage Method and Iterative Bayesian Model Average, R
packages are available. They are superpc, uniCox and iterativeBAMsurv respectively.
Matlab codes for BVSME-Surv and bvssurv are available http://www.stat.rice.edu/ ma-
rina/software.html.
• superpc- The package superpc uses the functions, superpc.train and superpc.predict
to predict a quantitative regression or survival outcome using supervised prin-
cipal components method. The accuracy of the estimation can be set by
n.threshold option, which decides the number of the thresholds to consider.
• uniCox- The package uniCox uses Univariate Shrinkage to fit a high dimensional
Cox model. The estimation accuracy and computation time are decided by the
option nlam, the number of λ values to consider.
• iterativeBAMsurv- The package iterativeBAMsurv use the function iterativeBAM-
surv.train to implement iterative BMA for variable selection on microarray data
and survival analysis.
• BVSME-Surv- The Matlab program BVSME-Surv use function bvsme aft to im-
plement Bayesian variable selection method in AFT model using Metropolis
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search for the micorarray data related to survival time.
• bvssurv The Matlab program bvssurv is used to implement Bayesian variable
selection method to choose important pathways and genes simultaneously by
incorporating information of the relationship of pathway and genes in the anal-
ysis of DNA microarray data.
• Bayesian Lasso for Semiparametric Structural Equation Models Illustrative Code
The C++ program of the Illustrative Code use a simulation study to implement
Bayesian Lasso method with a Markov Chain Monte Carlo (MCMC) algorithm
to SEM.
1.7.2 Data Sets
• NCI breast cancer data [van ’t Veer et al., 2002] - This data set has 295
consecutive patients with primary breast cancer. 151 had lymph-node-negaitve
disease, and 144 had lymph-node-positive disease. It also includes 24481 gene-
expression signatures.
• Monitoring the Future: A Continuing Study of American Youth
(12th-Grade Survey), 2010 - This survey is conducted by the University
of Michigan’s Institute for Social Research. This data set has total 12999 ob-
servations and some 1400 variables.
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Chapter 2
Bayesian Kernel Based Modeling
and Selection of Genetic Pathways
and Genes for Cancer
2.1 Introduction
DNA microarray data have been used as an approach to cancer classification previous
knowledge of those classes [Golub et al., 1999]. A lot of statistical methods have been
develop to identify important genes related certain diseases, prognosis etc. However,
gene selection may not be enough for more completed disease, especially in cancer.
Cancer is result of deregulation of one or more signaling pathways which are caused
by one or several set(s) of gene mutation[Sherr, 1996],[Hanahan and Weinberg, 2000].
Some types of cancers are more complicated, for instance, breast cancer. It is possible
that the genes or pathways which mutate to cause breast cancer are mostly different
between two breast cancer patients. The difference of genes or pathways mutation
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may be related to the patients’ cancer recurrence possibilities and times. Our goal is
to find out those important genes and pathways that might be related to the recur-
rence possibilities and tumor free time. In this chapter, we construct a semiparametric
Bayesian model which enable us to select important pathways and individual impor-
tant genes from the pathway by mixed priors through Bayesian variable selection
scheme.
We extend the idea of AFT models for survival data in the situation where there
are much more variables than observations. The model that we propose consider
both genes and pathways and combines information of pathway relationships and
gene networks in DNA microarray data analysis. The pathway and gene mapping
information are obtained from Kyoto Encyclopedia of Genes and Genomes(KEGG).
The gene networks information is used not only to define Markov random field prior
[Stingo et al., 2011] but also to structure the Markov chain Monte Carlo (MCMC)
moves. The interactions among the genes in one pathway are very complex and the
function form of the overall pathway effects is not clearly understood, so that we adopt
a reproducing kernel Hilbert spaces (RKHS) [Aronszajn, 1950] approach, therefore
we model the pathway effects nonparametrically. A big advantage of our approach is
that both linear and non-linear pathway effect can be used in the model, so that the
model is more flexible. Moreover, the model can perform different important genes
and pathways selection criteria by choosing different kernel functions.
Section 2 of this chapter introduced our semiparametric Bayesian model. Step
by step MCMC algorithm is introduced in Section 3. Section 4 provides simulation
studies and compare the performance of our proposed model against the method
proposed by [Stingo et al., 2011]. The application of the model for a real data set is
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discussed in Section 5. Finally, some discussion and concluding remarks are made in
section 6.
2.2 Bayesian Kernel Based Model
Accelerated failure time (AFT) models assumes multiplicative effect of the covariates
on the survival time, and the general AFT model is as,
log(Ti) = α + x
′
iβ + i, i = 1, · · · , n (2.1)
where Ti is the survival time, α is the intercept, p-vector xi is covariates, p-vector
β is regression parameters corresponding to the covariates, and i’s are the error
term which independent and identically distributed random variables with a common
distribution.
Suppose a data set consists of n subjects. For the subject i, we have the survival
time ti. Let ci be the censoring time independent of ti. Let δi = I{ti ≤ ci} to be cen-
sored indicator function and t∗i = min(ti, ci). We impute the censored data by using
the [Tanner and Wong, 1987] data augmentation approach. Let Y = (y1, y2, · · · , yn)′,
and yi is the augmented data as,
yi = log(t
∗
i ) if δi = 1
yi > log(t
∗
i ) if δi = 0
(2.2)
The covariates xi = (xi1, xi2, · · · , xip)′ in (2.1) is extended as fi = (f1(X1i ), f2(X2i ), · · · , fJ(XJi )),
j = 1, 2, · · · , J . fj(Xji ) is the overall effect of the pathway j with gene set Xji and J
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is the total number of the pathway. Assuming the error term is iid following standard
normal distribution, the model (2.1) becomes:
Yi = α + f1(X
1
i ) + · · ·+ fJ(XJi ) + ei, ei iid∼ N(0, σ2) (2.3)
We adopt RKHS approach to model function fj(X
j
i ). A Hilbert space is a vector
space H with an inner product 〈g1, g2〉 and the norm ‖g1‖ = 〈g1, g1〉1/2. An RKHS
H is a Hilbert space of ”smooth” functions defined by kernel. In an RHKS, there is
a function K : T × T → R with the properties:
• K(·,x) ∈ H and
• for any g ∈ H and x ∈ T , 〈K(·,x), g(·)〉 = g(x)
Following the representation theorem [Kimeldorf and Wahba, 1971], we have
fj(X
j
i ) =
n∑
l=1
βjlK(X
j
i ,X
j
l |θj) (2.4)
where K(Xji ,X
j
l | θj) is the Kernel, θj > 0, is the Kernel parameter and βjl is the
Kernel weight. In our research, we choose the Kernel as,
K(Xji ,X
j
l | θj) = exp(−
‖Xji −Xjl ‖
θ
) (2.5)
Our model will become:
Y = α1n +KB + e e ∼ N(0, σ2In)
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where Y = (y1, y2, · · · , yn)′; K is n by n× J matrix,
K =

K(X11 ,X
1
1 |θ1) K(X11 ,X12 |θ1) · · · K(X11 ,X1n|θ1) · · · K(XJ1 ,XJn |θJ)
K(X12 ,X
1
1 |θ1) K(X12 ,X12 |θ1) · · · K(X12 ,X1n|θ1) · · · K(XJ2 ,XJn |θJ)
...
...
. . .
...
. . .
...
K(X1n,X
1
1 |θ1) K(X1n,X12 |θ1) · · · K(X1n,X1n|θ1) · · · K(XJn ,XJn |θJ)

(2.6)
; and B is n× J vector,
BT = (β11 , β
1
2 , · · · , β1n, β21 , β22 , · · · , β2n, · · · βJ1 , βJ2 , · · · , βJn ) (2.7)
In order to use the information from KEGG, two matrices, S and R, are con-
structed [Stingo et al., 2011]. S is a J × p matrix representing the relationship
between genes and pathways. If gene k belongs to pathway j sjk = 1, otherwise
sjk = 0, where k = 1, · · · , p. The construction of the matrix R is different from [Li
and Zhang, 2010]. Matrix R indicates the relationship between genes. We consider
two types of gene relationships in our model. The first one is the genes whose coded
proteins combine and form a protein compound. If gene k1 and k2 are in this case,
rk1,k2 = 1. The other relationship between genes is that proteins coded by those genes
signal each other. In this case, rk1,k2 = q, where q > 0. And rk1,k2 = 0 other wise.
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2.2.1 Priors for Regression Parameters
Suppose the ti’s follow a log-normal distribution, the augmented data yi’s in (2.2) are
normally distributed as:
Y |K, α,B, σ2 ∼ N (α1 +KB, σ2In) (2.8)
where I is the identity matrix.
The conjugate priors for the model are given by
α|σ2 ∼ N (α0, aα)
B|σ2 ∼ N (B0, aBσ2In×J)
σ2 ∼ IG(ν0/2, ν0σ20/2)
(2.9)
where the hyperparameters are α0, aα, B0, aB, ν0 and σ0. We choose vague priors on
α and B: α0 = 0 and large aα; B0 = 0 and small aB. Small value of ν0 gives weakly
informative prior for σ2. Without losing generality and letting α0 = 0 and B0 = 0.
The priors become:
α|σ2 ∼ N (0, aα)
B|σ2 ∼ N (0, aBσ2I)
σ2 ∼ IG(ν0/2, ν0σ20/2)
(2.10)
2.2.2 Marginal Likelihood of the Augmented data
To simplify the calculation, we integrate out α, B and σ2.
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• First, we integrate out B
p(Y |X,K, α, σ2) =
∫
p(Y ,B|X,K, α, σ2)dB (2.11)
=
∫
p(Y |X,K,B, α, σ2)p(B|σ2)dB
∝ 1
(σ2)n/2
exp[−(Y −KB)
T (Y −KB)
2σ2
]
× 1
(aBσ2)Jn/2
exp[−B
TB
2aBσ2
]dB
∝ 1
(σ2)n/2
exp(
Y T (I + aβKKT )−1Y
2σ2
)
• We integrate out α
p(Y |X,K, σ2) =
∫
p(Y , α|X,K, σ2)dα (2.12)
=
∫
p(Y |X,Kα, σ2)p(α|σ2)dα
∝
∫
1
(σ2)n/2
exp(
Y T (I + abetaKKT )−1Y
2σ2
)
1
(aασ2)1/2
exp(− α
2
2aασ2
)dα
∝ 1
(σ2)n/2
exp(−Y
T (In + aα1
T1 + aβKKT )−1Y T
2σ2
)
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• Finally, we integrate out σ2
p(Y |X,K) =
∫
p(Y , σ2|X,K)dσ2 (2.13)
=
∫
p(Y |X,K, σ2)p(σ2)dσ2
∝
∫
(σ2)−ν0/2−1 exp(−ν0σ
2
0/2
σ2
)
1
(σ2)n/2
exp(−Y
T (In + aα1
T1 + aβKKT )−1Y T
2σ2
)dσ2
∝ (ν0σ20 + Y T (In + aα1T1 + aβKKT )−1Y T )−ν0/2−n/2
2.2.3 Mixture Priors for Variable selection
The regression coefficient B in (2.7) can be written as:
BT = (βT1 ,β
T
2 , · · · ,βTJ ) (2.14)
βj measures the effect of pathway j, but not all pathways are related to the dependent
variable. In order to identify the important pathways, we use Bayesian methods for
variable selection by applying a latent J-vector φ with binary entries. [Chipman et al.,
2001] review a vast amount of literature on Bayesian variable selection methodologies.
[George and McCulloch, 2005] assumed the regression coefficients arise from a scale
mixture of a point mass at 0 and a normal distribution, and our model follows this
assumption, so we have:
βj|φj, σ2 ∼ φjN (0, aβσ2In) + (1− φj)I(0) (2.15)
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where φj’s are independent Bernoulli random variables. When the pathway j is not
related to the dependent variable Y , the coefficient related to the pathway j, βj are
all 0’s.
2.2.4 Priors for Pathway and Gene Selection indicators
From the previous subsection, we know φj is the pathway selection indicator for jth
pathway. Let φ be the pathway selection indicator, and φ = (φ1, φ2, · · · , φJ).
φj = 1 when pathway is j selected in the model
φj = 0 otherwise
(2.16)
The priors for the pathway selection is:
p(φ|ωj) =
J∏
j=1
ω
φj
j (1− ωj)1−φj (2.17)
where ωj is a constant, which represents the priori probability of pathway j in the
model.
Let the gene selection indicator, γ = (γ1, γ2, · · · , γp)T . The prior distribution
should be able to consider both the pathway membership of each gene and the bi-
ological relationships between genes, which we use matrix R to indicate. We model
these relations using a Markov random field(MRF)[Li and Zhang, 2010]. Different
from [Li and Zhang, 2010], we consider two types of gene relationships. A MRF is a
set of random variables with a Markov property described by an undirected graph. If
two genes are not related, they are considered to be conditionally independent given
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all other genes [Besag, 1974]. The following probability indicates the connections on
the MRF.
p(γk|η, γl, l ∈ Nk) = exp(γkF (γk))
1 + exp(γkF (γk))
(2.18)
where F (γk) = (µ + η
∑
l∈Nk γk) and Nk is the set of genes in the same protein
compound of gene k and genes that receive/send signal from/to gene k in the MRF
given that the pathway of those genes are in the model. The global distribution on
the MRF is as:
p(γ|φ) ∝ exp(µ1Tp γ + ηγTRγ) (2.19)
where matrix R are introduced in the beginning of this section, µ is the parameter
that relates to the sparsity of the model, and η controls the prior probability of
gene selection depending on how many of its related genes are selected, so η sets the
smoothness of the distribution of γ over the undirected graph. If a protein from one
gene is isolated, then its prior distribution (2.18) becomes a Bernoulli distribution,
p = exp(µ)/[1 + exp(µ)]. On the other hand, the higher values of η is, the more likely
a gene is selected if many of its related genes are alright in the model.
Following [Stingo et al., 2011], three restrictions are needed to make sure both
interpretability and identifiablility of the model.
• Empty pathways, which means a pathways is selected but none of its member
genes are in the model.
• Orphan genes, which means a gene is selected in the model but none of pathways
having this gene is in the model.
• Different selected pathways have the same subset of genes selected in the model.
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Given these three restrictions, some of the combination of φ and γ are not in the
model. The joint prior probability for (φ,γ) is as:
p(φ,γ) ∝

∏J
j=1 ω
φj
j (1− ωj)1−φj exp(µ1Tp γ + ηγTRγ) for valid configurations
0 for invalid configurations
(2.20)
2.2.5 Prior for the Kernel Parameters
θj is the Kernel parameters for the pathway j. We use uniform distribution prior for
θj as:
p(θj) =
1
dθj − cθj
(2.21)
We only consider the θ’s that the corresponding pathways are in the model, so the
overall distribution of Kernel Parameters is:
p(θ) =

∏
j∈J
1
dθj − cθj
J is the subset of pathways that are in the model
0 otherwise
(2.22)
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2.2.6 Marginal Posterior Probabilities
After integrating out (α,β, σ2) in 2.2.2, our model has following parameters (φ,γ,θ).
given all the priors, (2.13) can be written as:
f(Y |X,K,φ,γ,θ) ∝ (ν0σ20 + Y T (In + aα1T1 + aβKKT )−1Y T )−ν0/2−n/2 (2.23)
This is a multivariate t-distribution
Y |X,K,φ,γ,θ ∼ Tν0 [0, σ0(In + aα1T1 + aβKKT )] (2.24)
with truncation given by (2.2). When yi is censored with δi = 0, it follows a univariate
truncated t-distribution and can be updated by Gibbs sampling.
The posterior probability distribution of the pathway and gene selection indicators
is as:
f(φ,γ|Y ,X,K,θ) ∝ f(Y |X,K,φ,γ,θ) · p(φ,γ) (2.25)
Similarly, the posterior probability distribution of kernel parameter is:
f(θ|Y ,X,K,φ,γ) ∝ f(Y |X,K,φ,γ,θ) · p(θ) (2.26)
2.3 MCMC algorithm and Posterior Inference
There are two MCMC steps in the model:
• sampling pathway and gene selection indicators from p(φ,γ|Y ,X,K,θ)
• sampling kernel parameters from p(θ|Y ,X,K,φ,γ)
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2.3.1 MCMC algorithm for Pathway and Gene Selection In-
dicators
Metropolis-Hastings algorithm is used when updating the pathway and gene selection
indicators parameter (φ,γ). The MCMC moves follows [Stingo et al., 2011]. In order
to select pathways and genes simultaneously and make sure the selections follow
the these restriction we mentioned before, they choose one of the following moves
randomly in each iteration:
1. Change the indicator of gene and pathway in the same time
• Add a pathway and a gene Randomly select a pathway from the subset of
pathways that are not in the model and neither is their member genes, so
φoj = 0 and p
o
j = 0, where p
o
j represent the number of genes that are included
in the model in pathway j. And then randomly select one gene k from the
pathway j (γoj,k = 0). Include both pathway and gene in the model, so that
φpj = 1 and p
p
j = 1. The proposed (φ
p
j , p
p
j) is accepted with probability:
min{1, f(φ
p,γp|Y ,X,K)
f(φo,γo|Y ,X,K) ·
ωj ·
∑J
j=1 I{φoj = 0, poj = 0}∑J
j=1 I{φpj = 1, ppj = 1,C1}
} (2.27)
where C1 is clarified below.
• Remove a pathway and a gene Find a subset of the pathways that are in the
model and only one of their member genes are selected in the model. Randomly
select one of them, so φoj = 1 and p
o
j = 1. In addition, the removal of gene does
not create identical subset of genes in different pathways, and this restriction
is C1. Remove both pathway and gene from the model, so that φpj = 0 and
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ppj = 0. The proposed (φ
p
j , p
p
j) is accepted with probability:
min{1, f(φ
p,γp|Y ,X,K)
f(φo,γo|Y ,X,K) ·
∑J
j=1 I{φoj = 1, poj = 1,C1}
ωj ·
∑J
j=1 I{φpj = 0, ppj = 0}
} (2.28)
2. Only change the indicator of gene in an included pathway
• Add a gene in an included pathway Find the subset(J ) of pathways that have
some of their member genes, but not all, in the model. And randomly select one
of them j, so φj = 1 and p
o
j < pj, where pj represent the total number of genes
in pathway j. And then randomly select one gene k from non-included genes
from the pathway j(γoj,k = 0). Include the gene in the model, so that γ
p
j,k = 1.
The proposed move is accepted with probability:
min{1, f(φ
o,γp|Y ,X,K)
f(φo,γo|Y ,X,K) ·
∑J
j=1 I{φoj = 1, poj < pj} ·
∑
j∈J
1
ppj(C2γ, CI2γ)∑J
j=1 I{φpj = 1, ppj > 1,C2θ, CI2θ}
∑
j∈J
1
pj − poj
}
(2.29)
where C2γ, CI2γ, C2θ and CI2θ are clarified below.
• Remove a gene from an included pathway Find the subset(J ) of pathways
that have more than one of their member genes in the model. And randomly
select one of them j, so φj = 1 and p
o
j > 1. Moreover, at least one of the
included genes in the pathway j may not be the sole gene in other included
pathways, so that removal of the gene do not create a empty pathway. The
these restrictions are corresponding to C2θ, CI2θ in (2.29) and (2.30). After the
pathway is selected, the subset of the included member genes is the genes that
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are not solely representative in other included pathways. And this restrictions
are corresponding to C2γ, CI2γ. A gene k is randomly selected from the subset
to be removed. C2θ and C2γ ensure the restrictions of the combination of
pathways and genes. The proposed move is accepted with probability:
min{1, f(φ
o,γp|Y ,X,K)
f(φo,γo|Y ,X,K) ·
∑J
j=1 I{φoj = 1, poj > 1,C2θ, CI2θ}
∑
j∈J
1
pj − ppj∑J
j=1 I{φpj = 1, ppj < pj} ·
∑
j∈J
1
poj(C2γ, CI2γ)
}
(2.30)
3. Only change the indicator of the pathways not the genes
• Add a pathway Find the subset of the non-included pathways that have some
of the member genes included in the model, and randomly select a pathway j
(φoj = 0 and p
o
j ≥ 0). Change the status of the pathway j, φpj = 1. In addition,
avoid to select a pathway whose included genes are exactly the same as the
include genes from an already included pathway. This is responding to CI3
below. Include the pathway j in the model, ppj = 1. The proposed move is
accepted with probability:
min{1, f(φ
p,γo|Y ,X,K)
f(φo,γo|Y ,X,K) ·
∑J
j=1 I{φoj = 1, poj ≥ 1,CI3}∑J
j=1 I{φpj = 1, ppj ≥ 1,C3}
} (2.31)
where C3 is clarified below.
• Remove an included pathway Find the subset of the included pathways that
all of the included member genes are associated with other included pathways
and randomly select one of them j(φoj = 1 and C3). This guarantees that no
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orphan gene in the model. Remove the pathway j from the model, ppj = 0. The
proposed move is accepted with probability:
min{1, f(φ
p,γo|Y ,X,K)
f(φo,γo|Y ,X,K) ·
∑J
j=1 I{φoj = 1, poj ≥ 1,C3}∑J
j=1 I{φpj = 1, ppj ≥ 1,CI3}
} (2.32)
2.3.2 MCMC algorithm for Kernel Parameters
From (2.22), θ have flat priors. Metropolis algorithm is used when updating θ. For
each included pathway, the proposed θpj is accepted with probability
min{1, f(θ
p
j |Y ,X,K,φ,γ)
f(θoj |Y ,X,K,φ,γ)
} (2.33)
2.3.3 Posterior Inference
In each iteration, the MCMC algorithm produce one model with included pathways
and gene, indicated by φ and γ respectively. And the whole procedure produce
a list of models. To estimate the marginal posterior probability for pathway j,
p(φj|Y ,X,K), we can count the number of the pathway j appeared in the included
pathways for every iteration after certain burnin point and then divide the count by
the total iteration after the burnin point. If the posterior probabilities of the pathways
pass some threshold, they are identified as the important pathways. Similarly, poste-
rior probabilities of gene k in the important pathway j, p(γk|Y ,X,K, I{φjsjk = 1})
can be calculated. The other way to find out important genes is to count the number
of gene k appear in the model ignoring whether it is in the important pathways. The
posterior probabilities of gene k can be calculate as p(γk|Y ,X,K}).
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2.4 Simulation Study
In this section, we evaluate the proposed model performance using simulated data
and comparing the result with [Stingo et al., 2011].
To simulate the data, we randomly chose 50 pathways from 243 pathways, and
1656 genes responding to these 50 pathways. The relationship between the pathways
and genes in the simulation data are based on the gene-pathway relations, S, and the
gene relations, R. We randomly chose 4 important pathways from the 50 pathways.
For each of the 4 important pathways, one important gene is selected randomly and
also the genes near it to code the same protein compound. Moreover, we selected the
genes that send or receive signals from the important protein compound. Then we
have 4 pathways and 27 important genes: 5 important genes out of 14 genes from
the first pathway, 6 out of 11 from the second, 8 out of 43 form the third and 8
out of 38 from the fourth. To simulate the data like these is based on the fact the
one gene mutation usually will not form cancer, but several related genes mutation
might cause cancer. We also add 2 fake important genes and 2 corresponding fake
important pathways in the model to check if the proposed model can avoid those 2
fake important pathways and genes. In reality, it is possible that patients have some
mutation genes not related to cancer.
To generate important genes’ microarray data, we first pick a gene which only
sends, but not receives signal among the important genes in a pathway and let X00
represent the value of that gene. Let X0 be either 2 or −2, and draw X00 from
X00 ∼ U(X0−.5, X0+.5). For the other genes that are in the same protein compound,
select one of them and denote it by X01 and X01 ∼ N (ρX00, .5), where ρ a multiplier
and here we let ρ = .95. For the kth genes in the same protein compound, its value
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is generated by X0j ∼ N (ρX0(j−1), .5). In the neighborhood protein compound, the
gene that receives the signal from X00 is denoted by X10 and X10 ∼ N (ρX00, .5)
and we can generate other genes value by X1j ∼ N (ρX1(j−1), .5). If we have other
neighborhood protein compound, their values are generated in similar format. For
the fake important gene, we only need to draw X00 from X00 ∼ U(X0 − .5, X0 + .5).
The rest of unimportant genes are simulated from a stand normal distribution. We
assume non-linear relationship between the response variable and the important genes
variable. The response variables are generated from:
• Let the effect of the first important pathway to be F1 and X1k to be the kth
important genes in the first important pathway.
F1 = cos(X11 )−1.5(X12 )2+exp(−X13 )X14−.8 sin(X15 ) cos(X13 )+2X11 ∗X15 (2.34)
• Let the effect of the second important pathway to be F2 and X2k to be the kth
important genes in the first important pathway.
F2 = cos(X21 )−1.5(X22 )2 +exp(−X23 )X24− .8 sin(X25 ) cos(X23 )+2X21 ∗X25 + .9X26
(2.35)
• Let the effect of the third important pathway to be F3 and X3k to be the kth
important genes in the first important pathway.
F3 = cos(X31 )− 1.5(X32 )2 + exp(−X33 )X34 − .8 sin(X35 ) cos(X33 ) (2.36)
+2X31 ∗X35 + .9X36 sin(X37 )− .8 cos(X36 )X37 + 2X48
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• Let the effect of the forth important pathway to be F4, and it can be generated
similar to the third pathway.
• The response variables y would be
y = F1 + F2 + F3 + F4 + ,  ∼ N (0, 1) (2.37)
We choose weak information priors for our prior parameters. On 2.2.1, we already
set α0 = 0 and B0 = 0. Moreover, we set aα = 100 and aβ = 0.1. The variance of the
inverse gamma distribution exists when the shape parameter greater than 2 and we set
the shape parameter, ν0/2 = 3, which is the smallest integer that greater than 2. The
scale parameter, ν0σ
2
0/2 = 0.6, which form a weakly informative prior. µ decides the
sparsity of the model. In simulation our goal is to select 2 to 6 important pathways for
each iteration, but different simulation data set require slightly different µ to achieve
this goal. We let the model change the µ value based on average pathways in the
model in very 2000 iterations. The change of value of µ will increase the instability of
the pathway selection, but once the suitable µ is selected, it will unlikely change. We
choose η = 0.08, which controls the prior probability of gene selection depending on
how many its related genes are selected. We set ω = .1 as the prior for the probability
of important pathway.
We have two different simulation scenarios: first one is that the important genes
are only in the important pathways; the other one is that the important genes are
not only in the important pathways, but the subset of them are in other pathways.
The detail of the scenarios setting is as:
• Simulation 1 We make sure the 27 important genes only appear in the four
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TP FP TN FN
True 4 0 46 0
Est. 3.24 0.26 45.74 0.76
Est. by [Stingo et al., 2011] 2.46 10.78 35.22 1.54
Table 2.1: Comparison between our model and [Stingo et al., 2011] model in simula-
tion 1
important pathways. The sample size n = 100. We replicate the simulation 50
times, generating 50 different data sets. µ = −2.8 is the initial value.
• Simulation 2 Similar to simulation, except we add subset of the important genes
to 3 different pathways and µ = −5 is the initial value.
We compare to result with [Stingo et al., 2011] model in the Simulation 1, table(2.1).
On average, in our method, we choose 3.42 out of 4 important pathways and that is
almost 1 more than [Stingo et al., 2011] model. Our model have 0.26 false pathway
selection, which is much less than theirs(10.78). In 50 different simulations, our model
selected none of the 2 fake important pathways. For each selected important path-
ways, at least one of the important genes are selected and none of the non-important
genes are selected. Our model does not select any of the fake important pathways
during the 50 different simulations; while [Stingo et al., 2011] model selects one of
the fake important pathways frequently. This is a very good advantage of our model,
because model does not select those mutated genes, when mutation happens during
cell reproduction process but not related to the metastasis.
Table(2.2) shows the result of simulation 2. Our model selected 3.02 out of 4
important pathways on average, which is slightly lower than simulation 1, while the
false selection becomes 1.02, which is greater than the simulation 1. Most of the false
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TP FP TN FN
True 4 0 46 0
Est. 2.92 1.04 44.96 1.08
Est. by [Stingo et al., 2011] 1.78 11.12 34.88 2.22
Table 2.2: Comparison between our model and [Stingo et al., 2011] model in simula-
tion 2
selections are related to non-important pathways with important genes. [Stingo et al.,
2011] model also performs worse than the simulation 1.
2.5 Application
We used the [van ’t Veer et al., 2002] breast cancer microarray data. In the data set
there are 337 patients with 24481 microarray probes. We focus on 54 lymph-node-
negative stage 0 patients. 21 of them developed distant metastasis and the rest of
them are censored. our goal is to identify the pathways and genes related to breast
cancer distant metastasis.
Follow [Troyanskaya et al., 2001] imputation method, we applied a 10-nearest
neighbor algorithm to impute missing gene expressions data. The pathway and gene
mapping information are obtained from Kyoto Encyclopedia of Genes and Genomes(KEGG).
The gene identifiers are Entrez Gene in KEGG and GenBank accession in breast can-
cer microarray data. We convert the GenBank accession to Entrez Gene by using
Gene ID converter http://idconverter.bioinfo.cnio.es/. We then were able to match
the gene expression data with the pathway and gene mapping information. A total
of 243 pathways and 4363 genes were included in this study.
We set ω = .1 as the prior for the probability of important pathway, and µ = −1.7
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(a) The number of selected pathways after
burnin (b) The number of selected genes after burnin
Figure 2.1: The trace plots for the number of selected pathways and selected genes
and η = 0.04 for the gene selection. We choose weak information priors for our prior
parameters. We set α0 = 0, B0 = 0 section(2.2.1), and aα = 1000, aβ = 0.1. Similar
to the simulation study, the variance of the inverse gamma distribution exists when
the shape parameter greater than 2 and we set the shape parameter, ν0/2 = 3, which
is the smallest integer that greater than 2. The scale parameter, ν0σ
2
0/2 = 0.6, which
form a weakly informative prior.
We used 100,000 iterations with burnin 50,000 iterations. Figure(2.1) shows the
number of selected pathways and genes after burnin. The number selection pathways
for each iteration mostly is between 10 and 20; while the number selection genes is
always between 80 and 110.
Figure(2.2) shows that the 9 selected pathways which have highest posterior prob-
abilities. We chose 0.4 as threshold, because there is a gap between 0.3 and 0.4 in
the figure. Figure(2.3) shows the posterior probabilities of selected genes. We also
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chose 0.4 as the threshold, and we got 94 important genes Table2.3. From literature
search, we noticed that at least one of the important genes in each selected pathways
are related to breast cancer or breast cancer metastasis.
Let us look at some of the important pathways:
• Steroid Hormone Biosynthesis pathway Figure(2.4). Steroid hormones belong
to the group of chemical compounds known as steroids. These compounds are
biologically synthesized by several organs of the human as well as other animals
and they perform essential functions to maintain homeostasis. These functions
include control of metabolism, inflammation, immune functions, salt and water
balance, development of sexual characteristics, and the ability to cope with ill-
ness and injury. Such functional activities of steroid hormones require a strict
balance of their synthesis to assure appropriate host response. Any abnormal
changes in the biosynthetic pathway for steroid hormones can lead to imbal-
ance of the hormonal level in the body. A consequence of such an event will
be the abnormality in cellular function and abnormal growth. Postmenopausal
women have altered level of steroid hormones and are more susceptible to de-
velop breast cancer. Studies have shown that higher blood levels of testosterone
may increase the risk of breast cancer in postmenopausal women. Furthermore,
some evidence suggests that higher blood levels of testosterone may also increase
breast cancer risk in premenopausal women. Estrogen plays a critical role in
hormone-receptor-positive breast cancer growth. These findings underscore the
importance of the association of several enzymes and other bioactive molecules
in the steroid hormone biosynthetic pathway for analyzing the possibility of the
involvement of some of these molecules in breast cancer growth and spread.
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Important Pathways Important Genes(Entrez) Total number of Genes
Steroid Hormone Biosynthesis 10720 10941 1109 1543 1545 1551
1576 1577 1584 1586 1588 3283 24
3284 3290 3291 3293 3294 6715
7364 7365 7366 7367 8630 8644
Tyrosine Metabolism 124 125 126 127 128 130 13
131 218 220 221 222 2954
4128
Glutathione Metabolism 2678 2877 2878 2879 2882 2937
2938 2939 2940 2941 2946 2947 24
2948 2949 2950 2952 2953 2954
373156 4257 4258 4259 51060 9446
Arachidonic Acid Metabolism 1558 1562 1571 1579 2678 2877 11
2878 2882 8644 873 874
Folate Biosynthesis 10170 10720 10941 124 125 126
127 128 130 131 1543 1544
1548 1551 1553 1558 1562 1576
1577 1579 1592 216 50700 53630 37
54884 56603 5959 6121 7364 7365
7366 7367 8228 8608 8854 9227
9249
Retinol Metabolism 10720 10941 7364 7365 7366 7367 6
Porphyrin & Chlorophyll 10720 10941 1109 124 125 126
Metabolism 127 128 130 131 1543 1544
1545 1548 1551 1553 1558 1562
1565 1571 1572 1576 1577 2052
218 220 221 222 22977 27294 57
2938 2939 2940 2941 2946 2947
2948 2949 2950 2952 2953 2954
3290 3291 373156 4257 4258 4259
7364 7365 7366 7367 8574 8644
873 874 9446
Drug Metabolism - 10720 10941 124 125 126 127
Cytochrome P450 128 130 131 1544 1548 1551
1553 1558 1562 1565 1571 1576
1577 218 220 221 222 2326
2327 2328 2329 2330 2938 2939 50
2940 2941 2946 2947 2948 2949
2950 2952 2953 2954 373156 4128
4257 4258 4259 7364 7365 7366
7367 9446
Drug Metabolism - 10720 10941 1548 1551 1553 1576 11
Other Enzymes 1577 7364 7365 7366 7367
Table 2.3: Summation of Important Pathways and Genes
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• Tyrosine Metabolism Figure(2.5). Tyrosine is an amino acid that plays an
essential role in the metabolism. Tyrosine metabolism is crucial component to
breast cancer and other cancer as well.
• Glutathione Metabolism Figure(2.6). Glutathione plays important roles in an-
tioxidant defense, nutrient metabolism, and regulation of cellular events includ-
ing gene expression, DNA and protein synthesis, cell proliferation and apopto-
sis, signal transduction, cytokine production and immune response, and protein
glutathionylation.Physiological relevance of glutathione makes the pathway and
components of glutathione metabolism a vital part of cancer-associated studies.
• Arachidonic Acid Metabolism Figure(2.7). Arachidonic acid and certain other
polyunsaturated fatty acids may be transformed into prostaglandins (PG) by
the enzyme prostaglandin endoperoxide synthase (PES). Level of prostaglandin
E2 is elevated in malignant human breast tissue. An increase of inflammatory
component may have a direct consequence in the development of inflammatory
breast cancer, a deadliest form of breast cancer.
Additionally, , the boxes represent the protein compound coded by genes. The red
number above the boxes are the important genes known to be related to breast cancer
that our model found. The number is Entrez. In the lower center of the graph, Entrez
gene 1588 is called CYP19A1. CYP19A1 gene codes for an enzyme called aromatase.
One of the critical functions of this aromatase is to convert testosterone to estradiol,
a form of estrogen [Meinhardt and Mullis, 2002]. Increased activity of aromatase has
been linked to breast cancer due to abundance of estradiol accumulation in the cancer
cells [Chen, 1998]. Estradiol increases tumor growth in breast cancer by promoting
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cell proliferation [L. et al., 2013]. In cancer cells it binds to estrogen receptor which
subsequently activates a group of hormone-responsive genes that promote DNA syn-
thesis and cell proliferation [DeMayo et al., 2002]. Therefore over-active CYP19A1
gene in breast cancer cells has a poor prognosis for patients due to over-expression
of aromatase-driven estradiol synthesis. Consequently, specific aromatase inhibitors
have been found to be useful in the treatment of breast cancer [M. et al., 1999].
Some of selected pathways and genes are known to be related to breast cancer
and breast cancer metastasis. Some of genes have no information according to the
literature search. From the biology research point of view, the biologists can use the
information from the posterior probability to prioritize the pathways and genes for
future research.
2.6 Discussion
In this chapter, we have proposed a Bayesian variable selection model with prior
biological information from pathways and genes relationship. We have considered
AFT to model the relationship between covariates and augmented failure time. We
have adopted an RKHS-based method to nonparametrically model the pathways effect
and have built into the model a variable selection mechanism that selects genes and
pathways simultaneously. Simulation studies and breast cancer microarray data have
been used to illustrate the proposed method.
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Figure 2.2: Marginal posterior probabilities for pathway selection, p(φj|Y ,X,K) >
0.4
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Figure 2.3: Marginal posterior probabilities for gene selection, p(γj|Y ,X,K) > 0.4
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Figure 2.4: Steroid hormone biosynthesis pathway with important genes that related
to breast cancer
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Figure 2.5: Tyrosine Metabolism pathway with important genes that related to breast
cancer
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Figure 2.6: Glutathione Metabolism pathway with important genes that related to
breast cancer
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Figure 2.7: Arachidonic acid metabolism pathway with important genes that related
to breast cancer
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Figure 2.8: Retinol metabolism pathway with important genes that related to breast
cancer
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Figure 2.9: Porphyrin and chlorophyll metabolism pathway with important genes
that related to breast cancer
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Figure 2.10: Metabolism of xenobiotics by cytochrome P450 pathway with important
genes that related to breast cancer
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Figure 2.11: Drug metabolism - cytochrome P450 pathway with important genes that
related to breast cancer
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Figure 2.12: Drug metabolism - other enzymes pathway with important genes that
related to breast cancer
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Chapter 3
Bayesian Elastic-Net and Fused
Lasso for Semiparametric
Structural Equation Models
3.1 Introduction
Structural equation models (SEMs) are a well developed statistical tool that are useful
for datasets with latent variables, which are not observed directly, but are estimated
from observed variables. SEMs consist of two parts, a measurement equation and a
structural equation. The measurement equation investigates the relationship between
the unobservable latent variables and observed manifest variables; whereas the struc-
tural equation measures the relationship between the endogenous latent variables and
exogenous latent variables, and the covariates. The primary research interest is typi-
cally the structural equation. SEMs are commonly used in Psychology, Biology, etc.,
where latent variables are common. For example, see [Martens, 2005], [Lee and Zhu,
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2000], [Liu et al., 2008], etc.
Traditionally, SEMs assume linear relationships among latent variables in the
structural equation. [Kenny and Judd, 1984] introduced a nonlinear SEM (NSEM)
that extended this methodology to include relationships such as interaction and
quadratic terms. [Lee, 2007] generalized NSEM to include a broader set of nonlinear
relationships. However, misspecification of the parametric form at the latent level,
whether the model is linear or nonlinear, can result in very poor estimation. Recently,
some semiparametric approaches have been developed. [Bauer, 2005], [Fahrmeir and
Raach, 2007], [Guo et al., 2012], etc used basis expansions to approximate the non-
linear structural relationships using semiparametric SEM (SSEM). To achieve simul-
taneous estimation and model selection [Guo et al., 2012] applied the Bayesian Lasso
method to the SSEM. The Bayesian Lasso performs well in SSEM, however, it ignores
correlation of the features which leads to inefficient parameter estimation and model
selection.
This is concerning when cubic splines are used, because they tend to be highly
correlated since each column is a transformed version of the same variables [Keele,
2008]. This chapter accesses this correlation by considering fused Lasso and elastic
net. The fused lasso has been shown to be a good method for multiple linear regres-
sion when the features have a natural order, specifically when there is side by side
correlation [Tibshirani et al., 2005a]. [Zou and Hastie, 2005], show that elastic net
often outperforms regular Lasso in both real world data set and simulation studies,
and they still have a similar sparse representation. In addition, the elastic net en-
courages a grouping effect, where strongly correlated predictors tend to be in or out
of the model together.
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3.2 Model
3.2.1 Semiparametric Structural Equation Models
Semiparametric structural equation models consist of two parts, a measurement equa-
tion and a structural equation. For a random sample of n independent subjects, the
measurement equation defines the relationship between the observed p× 1 vector of
manifest variables yi and the unobserved q×1 vector of latent variables wi as follows:
yi = Aci + Λwi + i, i = 1, 2, ..., n
where ci is an r × 1 vector of known functions of the s× 1 vector of fixed covariates
xi, A and Λ are unknown parameter matrices, i is a p × 1 vector of measurement
errors.
The latent variable wi is written in two parts, a q1×1 vector of endogenous latent
variables ηi and a q2 × 1 vector of exogenous latent variables ξi, i.e. wi = (ηTi , ξTi )T .
Then the structural equation, which defines the relationship between the exogenous
and endogenous latent variables, is
ηi = Πηi + F (xi, ξi) + ζi, i = 1, 2, ..., n, (3.1)
where ζi is a vector of residuals and F (xi, ξi) is a vector of unknown functions of the
covariates xi and exogenous latent variables ξi.
For this model, we require the following assumptions:
• i are independently distributed as N(0,Ψ) with Ψ = diag(ψ1, ψ2, ..., ψp).
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• wi and i are independent, and wi are independently distributed.
• ζi follows N(0,Ψζ) with Ψζ = diag(ψζ1, ψζ2, ..., ψζq1).
• ξi and ζi are independently distributed, and ξi follows N(0,Φ)
• Π0 = I − Π is nonsingular and |Π0| is independent of the elements of Π.
Theoretically, F (xi, ξi) can be any linear or nonlinear function of of xi and ξi with
or without interaction terms like ξi1ξi2. In this project, we consider a nonparametric
structural equation similar to [Guo et al., 2012] and we approximate the nonparamet-
ric function F (xi, ξi) using basis expansions. The structural equation 3.1, in general
case, can be represented as
ηi = Πηi +BH(xi, ξi) + ζi,
where H(xi, ξi) is an NH × 1 vector of basis functions, and Bqi×NH is the coefficient
parameter matrix associated with H(xi, ξi).
To illustrate the structural equation, consider a simple example with Π = 0, one
covariate, one endogenous and two exogenous latent variables. Any function F (xi, ξi)
can be decomposed into two parts, functions with only one variable as f1, f2 and f3,
which could be constant, and functions with interactions as f12, f13 and f23, which
must be functions of both two parameters, i.e.,
ηi = F (xi, ξi1, ξi2) + ζi
= f1(xi) + f2(ξi1) + f3(ξi2) + f12(xi, ξi1) + f13(xi, ξi2)
+ f23(ξi1, ξi2) + f123(xi, ξi1, ξi2) + ζi,
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It indicates that for modeling f1, f2 and f3, a linear basis expansion can be used,
such as piecewise polynomials, natural cubic splines, etc. In such cases,
fj(.) =
Mj∑
mj=1
βjmjhjmj(.), j = 1, 2, 3
where {hjmj(.),mj = 1, ...,Mj} are basis functions. For modeling f12, f13 and f23,
tensor product basis expansion can be used as follows:
fkl(., .) =
Mk∑
mk=1
Ml∑
ml=1
β(kl)mkmlhkmk(.)hlml(.), k, l = 1, 2, 3.
3.2.2 Bayesian Fused Lasso in the Semiparametric SEM
The unknown parameters in the measurement equation are Λy = (A,Λ) and Ψ, in
structural equation, the unknown parameters are Λw = (Π,B), Ψζ and Φ. Some
elements of Λy must be fixed for identifiability purposes.
For the measurement equation, an index matrix M = (mkj)p×(r+q) is created as
follows [Lee and Zhu, 2000],
mkj =
 1 if λykj is unknown0 otherwise
where λykj is the kj-th element of Λy. If there is an unknown parameter in k-th row
of Λy for k = 1, ..., p, this means that ryk =
∑r+q
j=1 mkj > 0. We denote Λ
∗
yk as the
68
ryk × 1 vector of unknown parameters and specified a conjugate prior for {Λ∗yk, ψk},
Λ∗yk|ψk ∼ Nryk(µ∗0yk, ψkH∗0yk) (3.2)
ψ−1k ∼ Gamma(α0k, β0k) (3.3)
where µ∗0yk, H
∗
0yk, α0k and β0k are hyperparameters.
For the structural equation, let Λwhbe the h-th row of Λw where h = 1, ..., q1. As
mentioned earlier, we assigned Bayesian fused Lasso priors for each Λwh and assigned
the inverse-Wishart prior for Φ.
Λwh|ψζh, τΛwh ,υΛwh ∼ N(0, ψζhDΛwh),
ψ−1ζh ∼ Gamma(α0ζh, β0ζh),
pi(τ 2Λwh) ∝
q1∏
j=1
λ2Πh
2
e
−λ2Πhτ
2
Πhj
/2
NX∏
j=1
λ2B1h
2
e
−λ2B1hτ
2
B1jj
/2
NT∏
j=1
λ2B2h
2
e
−λ2B2hτ
2
B2hj
/2
,
pi(υ2Λwh) ∝
NT∏
j=1
µ2B2h
2
e
−µ2B2hυ
2
B2hj
/2
,
Φ ∼ IW (R0, ρ0),
where Nh is the number of non-constant spline basis functions, and Nh = Nx + NT ,
where Nx is the number of basis functions related x’s, and NT is the number of
basis functions related to exogenous latent variables. Bh = (B
T
1h,B
T
2h)
T , where
B1h are the coefficients corresponding to the x’s and B2h are the coefficients cor-
responding to the exogenous latent variables. τΛwh and υΛwh are mutually inde-
pendent, and the covariance matrix D−1Λwh is a diagonal tridiagonal mixed matrix.
69
D−1Λwh = diag(D
11
q1×q1 ,D
22
NX×NX ,D
33
NT×NT ), where D
11
q1×q1 is a diagonal matrix with
main diagonal =
{ 1
τ 2Πhj
, j = 1, ..., q1
}
D22NX×NX is also a diagonal matrix with
main diagonal =
{ 1
τ 2B1hj
, j = 1, ..., NX
}
D33NT×NT is a tridiagonal matrix with
main diagonal =
{ 1
τ 2B2hj
+
1
υ2B2hj−1
+
1
υ2B2hj
, j = 1, ..., NT
}
off diagonals =
{
− 1
υ2B2hj
, j = 1, ..., NT − 1
}
All the λ’s are tuning parameters with gamma priors.
The extended Bayesian Fused Lasso prior has additional parameters, however,
with the priors specified as above, it is straightforward to derive the full conditional
distribution[Kyung et al., 2010]. As a result we can use MCMC methods to generate
samples from the joint posterior distribution of parameters.
The model can be easily extended to the case where X’s has side by side correlation.
We only need to change D22NX×NX to tridiagonal matrix with
main diagonal =
{ 1
τ 2B1hj
+
1
υ2B1hj−1
+
1
υ2B1hj
, j = 1, ..., NX
}
off diagonals =
{
− 1
υ2B1hj
, j = 1, ..., NX − 1
}
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pi(υΛwh) ∝
NX∏
j=1
µ2B1h
2
e
−µ2B1hυ
2
B1hj
/2
NT∏
j=1
µ2B2h
2
e
−µ2B2hυ
2
B2hj
/2
,
It is easy to derive the full conditional distribution and use MCMC methods to
generate samples from the joint posterior distribution of parameters for this scenario
as well.
3.2.3 Bayesian Elastic Net in the Semiparametric SEM
The measurement equation is exactly the same as in 3.2.2, however, for the structural
equation, the priors become:
Λwh|ψζh, τΛwh ,υΛwh ∼ N(0, ψζhDΛwh),
ψ−1ζh ∼ Gamma(α0ζh, β0ζh),
pi(τΛwh) ∝
q1∏
j=1
λ2Πh
2
e
−λ2Πhτ
2
Πhj
/2
NG∏
k=1
Nk∏
j=1
λ21Bhk
2
e
−λ21Bhkτ
2
Bhkj
/2
Φ ∼ IW (R0, ρ0),
where X is reordered. Strongly correlated covariates are grouped together, so we
have NG blocks of X’s, including one block for independent X’s if any exists. And
k = 1, · · · , NG. For block, k, Nk is the total number of members in the block. DΛwh
is a diagonal matrix with diagonal elements. If X’s in the corresponding block k are
correlated, the diagonal elements are (τ−2Bhkj + λ2Bhk)
−1; if X’s in the corresponding
block k are independent, the diagonal elements are τ 22Bhkj, in other words λ2Bhk = 0.
And similar to the Bayesian fused lasso, all the λ’s have gamma priors. It is still
straightforward to derive the full conditional distribution [Li and Lin, 2010], and
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use MCMC methods to generate samples from the joint posterior distribution of
parameters.
3.3 Posterior Distribution in the Semiparametric
SEM
3.3.1 Posterior Distribution in the measurement equation
Using the conjugate prior for Λ∗yk and ψk from 3.2 and 3.3, we can easily get the
posterior distributions as:
Λ∗yk|rest ∼ Nryk(Hyk(H∗−10yk µ∗0yk +Gyky∗k), ψk(H∗−10yk +GykGTyk)−1) (3.4)
ψ−1k |rest ∼ Gamma(α0k + n/2, β0k +
1
2
(y∗Tk y
∗
k + µ
∗T
0ykH
∗−1
0yk µ0yk − µTykH−1yk bmµyk))
(3.5)
where Gy = (C
T ,ΩT )T , C = {c1, · · · , cn} and Ω = {ω1, · · · ,ωn}.
3.3.2 Posterior Distribution in the Structure Equation of
Fused Lasso
Let Gω = (gω1, · · · , gωn), where gωi = (ηTi ,H(xi, ξi)T )T . Full conditionals in the
structure equation for the h-th row of Λω is:
Λwh|Ω, ψζh, τΛwh ,υΛwh ∼ Nq1+NH ((GTωGω+D−1Λwh)−1GTω(ηh−β0h1n), ψζh(GTGω+D−1Λwh)−1),
(3.6)
where Λωh = (Π
T
h ,B
T
h )
T . Nh is the number of non-constant spline basis functions,
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and Nh = Nx +NT , where Nx is the number of basis functions related x’s, and NT is
the number of basis functions related to exogenous latent variables.
LetBh = (B
T
1h,B
T
2h)
T , whereB1h are the coefficients corresponding to the x’s and
B2h are the coefficients corresponding to the exogenous latent variables. Note that
τΛωh = (τΠ2h1 , · · · , τΠ2hq1 , τΠ2Bh1 , · · · , τΠ2BhNH )
T , and the full conditional distribution for
τΛωh are:
1/τ 2Πhj|Πh, ψζh ∼ IN(
√
λ2Πhψζh
Π2hj
, λ2Πh)
1/τ 2B1hj |B1h, ψζh ∼ IN(
√
λ2B1hψζh
(B1hj)2
, λ2B1h)
1/τ 2B2hj|B2h, ψζh ∼ IN(
√
λ2B2hψζh
(B2hj)2
, λ2B2h)
1/υ2B2hj|B2h, ψζh ∼ IN(
√
λ24ψζh
(B2h(j+1) −B2h(j))2 , λ
2
4)
for j = 1, · · · , NT − 1.
The full conditional of ψζh is:
ψζh|Λwh,Gω ∼ IG(α0ζh + n+ q1 +NH + 1
2
, β1ζh)
where β1ζh = β0ζh +
1
2
[(ηh − β0h1n −GTωΛωh)T (ηh − β0h1n −GTωΛωh) + ΛTωhD−1ωhΛωh]
Let the prior of λ’s to be Gamma distribution and the full conditional distributions
of them is:
λ2Πh|τΠh ∼ Gamma(q1 + r0ω,
q1∑
j=1
τ 2Πhj/2 + δ0Π)
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λ2B1h|τB1h ∼ Gamma(NX + r0B1 ,
NX∑
j=1
τ 2B1hj/2 + δ0B1)
λ2B2h|τB2h ∼ Gamma(NT + r0B2 ,
NT∑
j=1
τ 2B2hj/2 + δ0B2)
λ24|υB2h ∼ Gamma(NT + r0B22 − 1,
NT−1∑
j=1
υ2B2hj/2 + δ0B22)
3.3.3 Posterior Distribution in the Structure Equation of
Elastic Net
Full conditionals in the structure equation for the h-th row of Λω is:
Λwh|Ω, ψζh, τΛwh ,∼ Nq1+NH ((GTωGω+D−1Λwh)−1GTω(ηh−β0h1n), ψζh(GTGω+D−1Λwh)−1),
1/τBhkj|Λωh, ψζh ∼ IG(
√
λ21Λhkψζh
Λ2ωhkj
, λ21Λhk)
for j = 1, · · · , Nk, where λ1Λhk = λ1Πhk, when Λwhk are the coefficients of the en-
dogenous latent variables; and λ1Λhk = λ1Bhk, when Λwhk are the coefficients of the
exogenous latent variables.
The full conditional of ψζh is:
ψζh|Λwh,Gω ∼ IG(α0ζh + n+ q1 +NH + 1
2
, β1ζh)
where β1ζh = β0ζh +
1
2
[(ηh − β0h1n −GTωΛωh)T (ηh − β0h1n −GTωΛωh) + ΛTωhD−1ωhΛωh]
Let the prior of λ’s to be Gamma distribution and the full conditional distributions
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of them is:
λ2Πh |τΠh ∼ Gamma(q1 + r0Π,
q1∑
j=1
τ 2Πhj/2 + δ0Π)
λ21Bhk |τΛhk ∼ Gamma(Nk + r1Bhk ,
Nk∑
j=1
τ 21Bhkj/2 + δ1Bhk)
λ22Bhk |B ∼ Gamma(Nk + r2Bhk ,
1
2ψζh
Nk∑
j=1
Λ2ωhkj + δ2Bhk)
where Λωhk represent the Λ’s belong to the group k.
3.3.4 MCMC Algorithm
The parameters from the measurement equation are denoted as θT1 = {Λy,Ψ}, while
the parameters from the structure equation are denoted as θT2 = {Λω,Ψξ,Φ}. Let the
parameter of interest be θ = (θT1 , θ
T
2 )
T .
Here are the variables we use in MCMC Algorithm:
• Y = {y1, · · · ,yn}, and yi is p× 1 vector of manifest variables.
• X = {x1, · · · ,xn}, and xi is s× 1 vector of fixed covariates.
• C = {c1, · · · , cn}, and ci is r × 1 vector of known function of xi.
• Ω = {ω1, · · · ,ωn}, and ωi is q × 1 vector of latent variables.
where i = 1, · · · , n
Ω are unobservable latent variables, we can generate it from the full conditional
distribution p(Ω|Y ,X,C,θ). Because the latent variables are independent among
the subjects, we can write the full conditional distribution as p(Ω|Y ,X,C,θ) =
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∏n
i=1 p(ωi|yi,xi, ci,θ). Let gyi = (cTi ,ωTi )T . The full conditional distribution of ωi
is:
p(ωi|yi,xi, ci,θ) ∝ p(yi|ci,ωi, θ1)p(ηi|xi, ξi, θ2)p(ξi|θ2)
∝ exp{−1
2
(yi − Λygyi)TΨ−1 (yi − Λygyi)−
1
2
ξTi Φ
−1
i Φi
−1
2
(ηi − β0 − Λωgωi)TΨ−1ζ (ηi − β0 − Λωgωi)} (3.7)
ωi can be sampled using Metropolis Hastings (MH) algorithm with a proposal
distribution q(ω∗i |σ2ω) ∼ N(ω(j)i , σ2ωΣω), where ω∗i is the proposed new value and ω(j)i
is the value from previous step (jth step). From [Guo et al., 2012],
Σ−1ω = Λ
TΨ−1Λ +
 ΠT0 Ψ−1ζ Π0 −ΠT0 Ψ−1ζ B∆H
−∆THBTΨ−1ζ Π0 Φ−1 + ∆THBTΨ−1ζ B∆H
 (3.8)
where ∆H = ∂H(xi, ξi)/∂ξ
T
i |ξi=0. The proposed ω∗i can be accepted with the prob-
ability min{1, p(ω
∗
i |yi,xi, ci,θ)
p(ω
(j)
i |yi,xi, ci,θ)
}. Ω can be sampled using Gibbs sampler.
For θ1, sample Λ
∗
yk|rest and ψk|rest from 3.4 and 3.5 respectively.
For θ2, the posterior distribution of the parameters are different between Bayesian
fused Lasso and Bayesian Elastic Net. We can sample the unknown parameters from
the posterior distribution we get on section 3.3.2 and section 3.3.3.
3.4 Simulation Study
To illustrate the fused Lasso and elastic net we have considered the case where the
covariates have correlations. Under this framework it is of interest to compare among
76
the Bayesian Lasso, the Bayesian fused Lasso and Bayesian elastic net.
3.4.1 Simulation 1
We follow the simulation setup on [Guo et al., 2012], setting n = 500, p = 9, q1 = 1,
q2 = 2 and A = diag(0
∗, 0∗, 0∗, µ4, . . . , µ9), ci = (1, . . . , 1)T ,
ΛT =

1.0∗ λ21 λ31 0∗ 0∗ 0∗ 0∗ 0∗ 0∗
0∗ 0∗ 0∗ 1.0∗ λ52 λ62 0∗ 0∗ 0∗
0∗ 0∗ 0∗ 0∗ 0∗ 0∗ 1.0∗ λ83 λ93
 ,
where µ4 = . . . = µ9 = λ21 = . . . = λ93 = ζ = .36 and {φ11, φ12, φ22} = {1, .25, 1}.
The function, f(ξi1, ξi2) = f1(ξi1) + f2(ξi2) + f12(ξi1, ξi2), where f1(ξi1) = sin(ξi1) −
ξi1, f1(ξi1) = exp(ξi2)/2.5 − 3.0 and f12(ξi1, ξi2) = 0, has been used to define the
underlying relationship between the endogenous and exogenous latent variables. Also,
this function is considered unknown and will be approximated using natural cubic
splines, i.e.,
fj(ξij) ≈ βj2ξij
K−2∑
m=1
βj,m+2 (dm(ξij)− dK−1(ξij))
f12(ξi1, ξi2) ≈ β(12)12 ξi1ξi2 +
K−2∑
m1=1
ξi2 (dm1(ξi1)− dK−1(ξi1))
+
K−2∑
m2=1
ξi1 (dm2(ξi2)− dK−1(ξi2))
+
K−2∑
m1=1
K−2∑
m2=1
(dm1(ξi1)− dK−1(ξi1)) (dm2(ξi2)− dK−1(ξi2)) ,
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with dk(ξij) =
[
(ξij − κk)+ − (ξij − κk)+
]
/ (κK − κk) where K is the number of knots
and (κk, k = 1, . . . , K) are the location of the knots. The knot locations are selected
using a truncated power series basis developed in [Hastie et al., 2009]. In general
cubic splines will be correlated, thus the use of the fused Lasso is appropriate.
We consider s = 35 with true parameter values
bl =

0.5 if l ∈ {1, 2, 3}
−0.7 if l ∈ {4, 5}
0.85 if l ∈ {6, · · · , 15}
0.7 if l = 32
0.5 if l = 33
0 otherwise
.
To induce correlation of the covariates x1, . . . , x31, x34, x35 are simulated from
a multivariate standard normal distribution where corr(xi, xj) = .5
|i−j|, i 6= j ∈
(6, . . . , 15), corr(xi, xj) = .7, i − j = 1, i ∈ (1, 2, 3), corr(xi, xj) = .9, i 6= j ∈ (4, 5)
and all other correlations equal to 0. The covariate of x32 ∼ 2Binomial(1, .5) and
x33 ∼ N(−0.5, 1).
Table 3.1 summarizes the parameter estimates from the 50 simulations using the
fused Lasso, elastic net and standard Lasso. The bi parameters which relate the co-
variates to the endogenous latent variable are slightly closer to the true value when
the fused Lasso is used, however for most of the parameters it is only a slight improve-
ment. The covariates with corr(xi, xj) = .7, i 6= j ∈ (1, 2, 3) have the most marked
improvement when the fused Lasso is used instead of the standard Lasso or elastic
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net. All models are efficient at shrinking the insignificant parameters to 0.
There is a fairly significant difference in the spline estimates between the standard
Lasso and the other two models. For the spline parameters that are not equal to zero
it is not possible to determine which of the models is better in terms of estimation.
However, in many of these cases the standard deviations of standard Lasso model are
significantly higher; while fused lasso and elastic net are similar to each other. For
the spline parameters that are equal to zero both fused Lasso and elastic net models
shrink the estimates nearer to zero than standard Lasso and many have significantly
lower standard deviations. Moreover, elastic net is slightly better than fused Lasso.
To measure the models efficiency at predicting the endogenous latent variable
using the covariates and exogenous latent variables, we consider three measures of
RMSE.
• RMSE(fˆ) =
√∑n
i=1
(
fˆ(ξi1, ξi2)− f(ξi1, ξi2)
)2
/n is a measure of the models
ability to approximate the nonlinear relationship between the endogenous and
exogenous latent variables,
• RMSE(Bˆ) =
√∑n
i=1
(
XBˆ −XB
)2
/n is a measure of the models ability to
relate the covariates to the endogenous latent variables and
• RMSE =
√∑n
i=1
((
XBˆ + fˆ(ξi1, ξi2)
)
− (XB + f(ξi1, ξi2))
)2
/n is a measure
of the models overall ability to predict the endogenous latent variable.
The most significant improvement in the fused Lasso and elastic net appears to
be in the RMSE(fˆ) which suggests that it is much better at defining the relationship
between the endogenous and exogenous latent variables. And RMSE(fˆ) of elastic net
is slightly lower than fused Lasso’s. A possible reason there was little impact from
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on the covariate parameters is that it is very difficult to simulate complex correlation
structures. If more covariance structures are examined we believe the difference could
be significant.
3.4.2 Simulation 2
In order to compare the difference defining the relationship between the endogenous
and exogenous latent variables among these three model. We randomly choose one
of the simulation study and let the coefficient of the covariate to be zeros and plot
the surface of f(ξi1, ξi2). Figure(3.1) shows the true relationship between exogenous
latent variables and endogenous latent variable based on function η = F (x, ξ); figure
(3.2) shows the relationship between them based on the simulation data, and some
of the surface does not have data. figure(3.3, 3.4 and 3.5) show the estimated surface
via original Lasso, Fused Lasso and Elastic Net. In figure(3.3), Lasso perform badly
when η1 and η2 both greater than 0. From figure(3.2), there are no data when both
η1 and η2 are greater than 2.5. Fused Lasso and Elastic perform similarly. In this
simulation, Fused Lasso might perform a little better, when both η1 and η2 are less
than 0.
3.5 Application
We apply Lasso and Elastic net models to analyze Monitoring the Future: A Con-
tinuing Study of American Youth (12th-Grade Survey). There are three exogenous
latent variables of interests, cigarette morbidity, marijuana morbidity and behavior
risk index; one endogenous latent variable, alcohol morbidity. We want to analyze
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Fused Elastic Net Standard
Para. True Est. STD Est. STD Est. STD
b1 0.5 0.4604 0.0885 0.4417 0.1241 0.4524 0.1767
b2 0.5 0.5596 0.1230 0.5768 0.1739 0.5685 0.2484
b3 0.5 0.4512 0.0909 0.4374 0.1280 0.4469 0.1798
b4 -0.7 -0.6817 0.0808 -0.6800 0.0894 -0.6793 0.0949
b5 -0.7 -0.7120 0.0809 -0.7099 0.0908 -0.7143 0.0955
b6 0.85 0.8430 0.0429 0.8460 0.0485 0.8460 0.0481
b7 0.85 0.8466 0.0537 0.8480 0.0612 0.8481 0.0608
b8 0.85 0.8465 0.0519 0.8405 0.0598 0.8409 0.0586
b9 0.85 0.8408 0.0542 0.8448 0.0634 0.8455 0.0643
b10 0.85 0.8579 0.0555 0.8543 0.0623 0.8523 0.0638
b11 0.85 0.8470 0.0513 0.8440 0.0574 0.8439 0.0562
b12 0.85 0.8454 0.0516 0.8433 0.0537 0.8428 0.0535
b13 0.85 0.8430 0.0510 0.8499 0.0549 0.8495 0.0547
b14 0.85 0.8499 0.0502 0.8404 0.0568 0.8415 0.0566
b15 0.85 0.8513 0.0488 0.8582 0.0507 0.8581 0.0490
b16 0 0.0043 0.0382 0.0014 0.0387 0.0026 0.0425
b17 0 0.0049 0.0380 0.0051 0.0347 0.0063 0.0388
b18 0 0.0050 0.0432 0.0036 0.0418 0.0036 0.0454
b19 0 -0.0003 0.0382 -0.0003 0.0362 -0.0001 0.0389
b20 0 0.0048 0.0397 0.0004 0.0400 0.0006 0.0440
b21 0 -0.0006 0.0393 -0.0034 0.0367 -0.0036 0.0400
b22 0 -0.0030 0.0377 -0.0017 0.0399 -0.0025 0.0427
b23 0 -0.0024 0.0429 -0.0021 0.0417 -0.0014 0.0452
b24 0 -0.0028 0.0413 0.0022 0.0353 0.0030 0.0380
b25 0 0.0027 0.0388 -0.0042 0.0374 -0.0048 0.0399
b26 0 -0.0030 0.0367 -0.0031 0.0368 -0.0017 0.0422
b27 0 0.0039 0.0388 0.0026 0.0337 0.0022 0.0376
b28 0 -0.0015 0.0385 0.0024 0.0368 0.0018 0.0403
b29 0 0.0061 0.0408 0.0052 0.0377 0.0052 0.0402
b30 0 0.0008 0.0360 -0.0029 0.0367 -0.0033 0.0401
b31 0 0.0036 0.0361 -0.0009 0.0337 -0.0016 0.0364
b32 0.7 0.6908 0.0452 0.6870 0.0442 0.6948 0.0443
b33 -0.5 -0.4932 0.0407 -0.4932 0.0412 -0.5001 0.0409
b34 0 -0.0064 0.0368 -0.0028 0.0363 -0.0029 0.0406
b35 0 0.0055 0.0384 0.0047 0.0384 0.0052 0.0421
β0 - -2.1529 0.0917 -2.1641 0.0940 -2.2231 0.1641
β12 - -0.1947 0.0772 -0.2165 0.0788 -0.2744 0.1721
β13 - -0.0607 0.0233 0.0117 0.0403 0.3379 0.4499
β14 - -0.0380 0.0283 -0.0308 0.0267 -0.0199 0.0465
β15 - -0.0213 0.0322 -0.0793 0.0456 -0.3637 0.3492
β22 - 0.0805 0.0404 0.0781 0.0611 0.1753 0.1352
β23 - 0.1528 0.0324 0.1163 0.0354 -0.0002 0.1777
β24 - 0.1985 0.0556 0.1766 0.0478 0.1118 0.0704
β25 - 0.1866 0.0650 0.2782 0.1173 0.3291 0.2340
β
(12)
22 0 0.0411 0.0632 0.0208 0.0551 0.1011 0.1753
β
(12)
23 0 -0.0320 0.0634 -0.0256 0.0553 -0.1101 0.1630
β
(12)
24 0 -0.0446 0.0808 -0.0198 0.0618 -0.0912 0.1752
β
(12)
25 0 -0.0369 0.0732 -0.0148 0.0688 -0.0600 0.2716
β
(12)
32 0 -0.0207 0.0331 -0.0093 0.0234 -0.0823 0.1394
β
(12)
33 0 0.0197 0.0190 0.0190 0.0273 0.0406 0.2214
β
(12)
34 0 0.0415 0.0304 0.0279 0.0344 0.1178 0.1546
β
(12)
35 0 0.0444 0.0329 0.0378 0.0431 0.2527 0.2123
β
(12)
42 0 0.0009 0.0318 -0.0110 0.0263 -0.0676 0.1108
β
(12)
43 0 0.0205 0.0329 0.0155 0.0319 -0.0275 0.1377
β
(12)
44 0 0.0362 0.0439 0.0246 0.0390 0.0510 0.1011
β
(12)
45 0 0.0382 0.0472 0.0352 0.0480 0.1807 0.2341
β
(12)
52 0 -0.0029 0.0461 -0.0118 0.0310 -0.0572 0.1702
β
(12)
53 0 0.0190 0.0569 0.0116 0.0381 -0.1153 0.1802
β
(12)
54 0 0.0469 0.0848 0.0215 0.0451 -0.0199 0.1947
β
(12)
55 0 0.0760 0.1133 0.0323 0.0538 0.1275 0.4199
RMSE(fˆ) 0 0.6676 0.3864 0.6493 0.3778 1.5127 1.5713
RMSE(Bˆ) 0 0.2323 0.0299 0.2350 0.0291 0.2436 0.0278
RMSE 0 0.6966 0.3738 0.6764 0.3693 1.5311 1.5627
Table 3.1: Simulation Result for Fused Lasso, Elastic Net and Standard Lasso
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Figure 3.1: True surface for η = F (x, ξ) Figure 3.2: True surface for simulated data
Figure 3.3: Estimated surface via Lasso
Figure 3.4: Estimated surface via Fused
Lasso
Figure 3.5: Estimated surface via Elastic
Net
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how cigarette morbidity, marijuana morbidity and behavior risk index affect alcohol
morbidity. We used the subset from the Monitoring the Future data: 1878 students
who had drinking experience.
The endogenous latent variable, alcohol morbidity, is measured by following items:
• The occasions that students had alcoholic beverages to drink, more than just a
few sips in their lifetime.
• The occasions that students had alcoholic beverages to drink, more than just a
few sips last year.
• The occasions that students had alcoholic beverages to drink, more than just a
few sips last month.
• The number of times that the students had five or more drinks in a row in the
last two weeks.
The first exogenous latent variable, cigarette morbidity, is measure by following
items:
• The occasions that students smoked cigarettes in their lifetime.
• The occasions have students smoked cigarettes during the past 30 days.
The second exogenous latent variable, marijuana morbidity, is measure by follow-
ing items:
• The occasions that students smoked marijuana in their lifetime.
• The occasions that students smoked marijuana last year.
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• The occasions that students smoked marijuana last month.
The third exogenous latent variable, behavior risk index, is measure by following
items:
• During the last four weeks, the number of whole days of school students have
missed because they skipped.
• During the last four weeks, the number of whole days of school students have
missed because other reasons.
• During a typical week, the number of evenings students go out for fun and
recreation.
• On the average, how often students go out with a date.
• During an average week, how much students usually drive.
As a result, there are totally 14 manifest variables. The Λ in the measurement
equation is:
ΛT =

1 λ21 λ31 λ41 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 λ62 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 λ83 λ93 0 0 0 0 0
0 0 0 0 0 0 0 0 0 1 λ11,4 λ12,4 λ13,4 λ14,4

(3.9)
LetA = diag(0, · · · , 0, µ5, · · · , µ14) and ci = (1, · · · , 1)T . In addition, we have five
covariates, which are gender, geographic area, living with siblings, father education
level and mother education level. Let xi = (x1i, · · · , x5i) To study the interaction
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between the exogenous latent variables and endogenous latent variable, we proposed
following structure equation model:
ηi = xib
T + f1(ξ1i) + f2(ξ2i) + f3(ξ3i) + f12(ξ1i, ξ2i) + f13(ξ1i, ξ3i) + f23(ξ2i, ξ3i) (3.10)
where b = (b1, · · · , b5). Similar to simulation study, natural cubic splines are used
in function f(·) with 5 knots. MCMC chains of 20,000 iterations are generated and
the burnin is 10,000. We use both Bayesian fused lasso and Bayesian elastic net to
solve the problem, and compare the result with Bayesian Lasso. Table 3.2 shows the
estimates from measurement equation. The estimates are very similar among three
methods.
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Para. Fused LASSO Est. Elastic Net Est. LASSO Est.
λ2,1 0.8477 0.8358 0.836
λ3,1 0.5202 0.5067 0.5069
λ4,1 0.4098 0.3982 0.3983
λ6,2 1.0505 0.9976 1.047
λ8,3 1.2825 1.2866 1.2965
λ9,3 1.2088 1.2127 1.2219
λ11,4 0.7485 0.5973 0.6634
λ12,4 0.3364 0.4089 0.3993
λ13,4 0.1659 0.1558 0.1583
λ14,4 0.109 0.1978 0.1796
µ5 3.133 3.1667 3.1099
µ6 1.9161 1.9526 1.8925
µ7 5.3888 5.4149 5.4285
µ8 4.4709 4.5048 4.5217
µ9 2.8753 2.9067 2.9222
µ10 2.0841 2.1565 2.1203
µ11 1.7787 1.8275 1.8065
µ12 3.9871 4.0141 3.999
µ13 3.1242 3.1356 3.1303
µ14 3.5832 3.5943 3.5879
Para.: parameter
Est. posterior estimates
Table 3.2: Non-Spline Parameter Estimation
The structure equation results for fused Lasso and Elastic Net are on Table 3.3
and Table 3.4 respectively. Some of the β’s from Elastic Net are not converged.
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Comparing to the result form Bayesian Lasso Table 3.5. All the β’s from Bayesian
Lasso are not converged. Fused lasso performed best in this application, all the
β’s from Fused Lasso converge, and result shows that there is interaction between
marijuana morbidity and behavior risk index. The main effect of cigarette morbidity is
also significant. The graphs of the two-way interaction of these three exogenous latent
variables shows their relation with endogenous latent variable. Figure 3.6 shows there
is not obviously interaction between cigarette morbidity and marijuana morbidity,
but both main effects are significant. When cigarette morbidity or/and marijuana
morbidity increase, alcohol morbidity increases. Figure 3.7 shows similar pattern
with cigarette morbidity and behavior risk index. Figure 3.8 shows the interaction
between marijuana morbidity and behavior risk index. When behavior risk index is in
the higher level, as marijuana morbidity increases, alcohol morbidity increases faster.
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Para. Est. Para. Est. Para. Est. Para. Est.
b1 0.1216
∗ β(12)1 -0.0553 β
(13)
1 -0.0156 β
(23)
1 −0.1149∗
b2 0.0243 β
(12)
2 -0.008 β
(13)
2 0.0073 β
(23)
2 -0.0056
b3 0.0835 β
(12)
3 0.0081 β
(13)
3 0.0179 β
(23)
3 0.0246
b4 0.0845 β
(12)
4 0.0152 β
(13)
4 0.0248 β
(23)
4 0.0327
b5 -0.0322 β
(12)
5 0.0258 β
(13)
5 0.033 β
(23)
5 0.0286
β0 5.8534
∗ β(12)6 0.0063 β
(13)
6 0.007 β
(23)
6 0.0165
β12 0.2729
∗ β(12)7 -0.0045 β
(13)
7 -0.0041 β
(23)
7 0.009
β13 0.0303 β
(12)
8 -0.0044 β
(13)
8 -0.0029 β
(23)
8 0.0068
β14 -0.0037 β
(12)
9 0.0166 β
(13)
9 0.0163 β
(23)
9 0.0113
β15 0.0067 β
(12)
10 0.0007 β
(13)
10 -0.006 β
(23)
10 0.0002
β22 0.1142
∗ β(12)11 -0.0086 β
(13)
11 -0.0139 β
(23)
11 -0.0047
β23 0.0654
∗ β(12)12 -0.0065 β
(13)
12 -0.012 β
(23)
12 -0.0066
β24 0.0382 β
(12)
13 0.0176 β
(13)
13 0.0048 β
(23)
13 -0.002
β25 0.0441 β
(12)
14 -0.0025 β
(13)
14 -0.0273 β
(23)
14 -0.0168
β32 0.1745
∗ β(12)15 -0.0151 β
(13)
15 -0.0529 β
(23)
15 -0.0252
β33 0.0986
∗ β(12)16 -0.0217 β
(13)
16 -0.0824 β
(23)
16 -0.0314
β34 0.0417
β35 -0.0039
Para.: parameter
Est. posterior estimates
* marked values indicates 90% of the distribution is greater than 0 or
less than 0.
Table 3.3: Spline Parameter Estimation using Bayesian Fused Lasso
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Para. Est. Para. Est. Para. Est. Para. Est.
b1 0.0169 β
(12)
1 -0.0026 β
(13)
1 -0.1193 β
(23)
1 0.0023
b2 0.0018 β
(12)
2 -0.0054 β
(13)
2 -0.4759 β
(23)
2 0.0031
b3 0.0035 β
(12)
3 -0.005 β
(13)
3 0.462 β
(23)
3 0.0039
b4 0.004 β
(12)
4 -0.0045 β
(13)
4 2.5223
§ β(23)4 0.0046
b5 -0.0042 β
(12)
5 0.0022 β
(13)
5 -0.3639 β
(23)
5 -0.0008
β0 5.9121 β
(12)
6 0.0012 β
(13)
6 -0.4635 β
(23)
6 0.0015
β12 -0.0291 β
(12)
7 0.0013 β
(13)
7 -0.6698 β
(23)
7 0.0018
β13 -0.0016 β
(12)
8 0.0011 β
(13)
8 −1.2979§ β(23)8 0.0027
β14 0.0043 β
(12)
9 0.003 β
(13)
9 -0.1049 β
(23)
9 -0.0011
β15 0.0156 β
(12)
10 0.0021 β
(13)
10 -0.1743 β
(23)
10 0.0021
β22 -0.0002 β
(12)
11 0.0022 β
(13)
11 -0.5128 β
(23)
11 0.0021
β23 -0.0026 β
(12)
12 0.0022 β
(13)
12 −1.5011§ β(23)12 0.003
β24 -0.0025 β
(12)
13 0.0044 β
(13)
13 1.0263
§ β(23)13 -0.0011
β25 -0.0026 β
(12)
14 0.0045 β
(13)
14 1.3305
§ β(23)14 0.0017
β32 2.4961
§ β(12)15 0.0042 β
(13)
15 0.4733 β
(23)
15 0.0024
β33 18.3222
§ β(12)16 0.0041 β
(13)
16 -0.53 β
(23)
16 0.0031
β34 −35.6403§
β35 16.0324
§
Para.: parameter
Est. posterior estimates
§ indicates the estimates are not converged..
Table 3.4: Spline Parameter Estimation using Bayesian Elastic Net
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Para. Est. Para. Est. Para. Est. Para. Est.
b1 0.0159 β
(12)
1 −2.7382§ β(13)1 1.0451§ β(23)1 0.2214§
b2 0.0014 β
(12)
2 8.284
§ β(13)2 22.0392
§ β(23)2 0.3895
§
b3 0.0008 β
(12)
3 −3.644§ β(13)3 −3.7627§ β(23)3 4.5003§
b4 0.0074 β
(12)
4 −1.4991§ β(13)4 −15.6498§ β(23)4 −2.7686§
b5 -0.0038 β
(12)
5 9.7528
§ β(13)5 −7.5459§ β(23)5 1.2014§
β0 5.9608 β
(12)
6 −5.0116§ β(13)6 −11.514§ β(23)6 −7.5515§
β12 −1.3933§ β(12)7 −3.7479§ β(13)7 −10.617§ β(23)7 −18.5468§
β13 −9.2749§ β(12)8 −1.6634§ β(13)8 4.8088§ β(23)8 −6.5395§
β14 8.9574
§ β(12)9 −7.53§ β(13)9 2.7655§ β(23)9 −4.1878§
β15 0.6507
§ β(12)10 −0.5455§ β(13)10 0.9769§ β(23)10 3.9873§
β22 −1.7371§ β(12)11 3.0895§ β(13)11 0.6814§ β(23)11 4.1692§
β23 3.1955
§ β(12)12 5.5655
§ β(13)12 18.2107
§ β(23)12 34.5997
§
β24 −1.5914§ β(12)13 0.4208§ β(13)13 3.3887§ β(23)13 2.5759§
β25 −0.5296§ β(12)14 −0.4141§ β(13)14 −1.0071§ β(23)14 8.6044§
β32 4.3805
§ β(12)15 1.5452
§ β(13)15 −2.2612§ β(23)15 −0.4574§
β33 3.9027
§ β(12)16 −1.8298§ β(13)16 −2.0676§ β(23)16 −21.5666§
β34 −5.7997§
β35 1.9083
§
Para.: parameter
Est. posterior estimates
§ indicates the estimates are not converged.
Table 3.5: Spline Parameter Estimation using Bayesian LASSO
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Figure 3.6: Estimated surface for
cigarette morbidity and marijuana mor-
bidity
Figure 3.7: Estimated surface for
cigarette morbidity and behavior risk in-
dex
Figure 3.8: Estimated surface for mari-
juana morbidity and behavior risk index
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3.6 Discussion
We adapt Bayesian fused Lasso and Bayesian elastic net for using in semiparametric
structural equation models. Basis expansions are used to approximate the nonpara-
metric relationships between the endogenous latent variables and the exogenous latent
variables and covariates. When cubic splines are used as the basis expansion, it is
beneficial to use the fused Lasso or the elastic net to estimate the parameters since
cubic splines are correlated in general. In the simulation study, both fused Lasso
and elastic net reduce the standard deviations of the spline parameters and shrink
the estimates of the spline parameters closer to zero when the true values of those
parameters are equal to zero. More importantly, RMSE(fˆ) of fused Lasso and elastic
net is about half of RMSE(fˆ) of standard Lasso.
There are benefits to use the fused Lasso to estimate the coefficients of the covari-
ates, however, it is difficult to generate realistic correlation structures. The usefulness
of this method will depend greatly on the type of correlation. In our simulation study,
the fused Lasso has a remarkable improvement over the standard Lasso for the tridi-
agonal structure with correlation equal to 0.70. However, it is difficult to simulate
tridiagonal structures since we often get negative eigenvalues. We believe that if a
natural order are present in a real data set the fused Lasso would lead to much better
results.
In the application, we treated the ordinal valuables as continuous. All of these
three methods have similar estimates for the measurement equations. However, the
Bayesian Lasso and Bayesian Elastic Net are not converged when estimating the struc-
ture equation. Bayesian fused Lasso is converged and show the interaction between
behavior risk index and marijuana morbidity.
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The proposed model includes two way interaction of the exogenous latent vari-
ables, and it is straightforward to extend to three way interaction, when the problem
has at least three exogenous latent variables. However, that will increase a great
amount of the number of coefficients needed to estimate, depending on the number
of knots. In our study, the options of the psychology survey are mostly ordinal data.
In some cases, the options might be dichotomous and that would violate the contin-
uous assumption of the manifest variable. Further research is needed to extend the
manifest variable to binary and nominal response. Also it is worthwhile to extend it
to other basis expansion methods.
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Chapter 4
Discovering Gene Network and
Interactions using Bayesian Graph
Laplacian Model
4.1 Introduction
In chapter 2, we select important pathways and genes with the help of pathways
information and genes relationship. The matrix R in chapter 2 indicates what genes
are related, but does not specify how strong they are related. Also, there are other
limitation: it is possible that different diseases cause genes interact differently within
the same pathway; biology technology upgrades frequently and new findings in genetic
research happen all the time, which means the genes relationship matrix R might be
renewed every few years. It will be a great advantage in statistical analysis if we
can remove the independence assumption, a priori between variables or a completely
known dependence structure, i.e., matrix R, when analyze the data. [Liu et al., 2014]
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propose a Bayesian method that models the dependence structure through a graph
Laplacian matrix. The main methods to find out similarity between data points and
spectral clustering are Graph Laplacian matrices. We believe this method can be used
to show the underlie dependent structure among the genes, which can be used as a
potential guideline for further biological study about the interaction among genes.
4.2 Graph Laplacian Matrix
Spectral clustering algorithms concentrate on finding good clusters in statistical learn-
ing and data mining. One of the main tools of spectral clustering algorithms are graph
Laplacian or the laplace matrices of graphs. Followed [von Luxburg, 2007], let simi-
larity graph G = (V,E) represent a set of n data points, and vi represents a vertex,
i = 1, · · · , n and E is a set of edge. Let sij ≥ 0 be the measure of similarity between
two vertices vi and vj, and they are connected by an edge sij > 0. Define a weighted
adjacency matrix W = (wji)i,j=1,··· ,n and wij = wji ≥ 0. di =
∑n
j=1 wij is the degree
of a vertex vi. LetD = diag(d1, · · · , dn) and the graph Laplacian of G is L = D−W .
The spectral clustering algorithms works effectively, but there are several limitations.
In regression analysis, it clusters the independent variables rather than their coeffi-
cients; secondly, it is under an assumption that there is available information about
the weighted adjacency matrix, but that is not necessary the case when we analyze
gene relationship; lastly, the restriction of wij ≥ 0 is not realistic by assuming positive
partial correlations between all pairs of variables. [Liu et al., 2014] overcome these
difficulties by extending the graph Laplacian model.
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4.3 Graph Laplacian Model
Consider a linear regression:
Y = Xβ + , (4.1)
where dependent variable Y is a n × 1 vector, independent variables X is n × p
matrix, corresponding β is a p× 1 vector and  ∼ N(0, σ2In).
4.3.1 Prior Distribution
The prior distribution for β is:
β = N(0,
σ2
r
Λ−1), (4.2)
where r ≥ 0 and Λ is the graph Laplacian matrix:
Λ =

1 + λ11 +
∑
j 6=1 |λ1j| λ12 · · · λ1p
λ21 1 + λ22 +
∑
j 6=2 |λ2j| · · · λ2p
...
...
. . .
...
λp1 · · · · · · 1 + λpp +
∑
j 6=p |λpj|

(4.3)
where λij = λji and λii > 0
The prior for λ’s is as follows:
pi(λ) ∝ Ca,b|Λ|−1/2
p∏
i=1
λ
−3/2
ii exp(−
a2
2λii
)I(λii > 0)
∏
j<i
|λij|−3/2 exp(− b
2
2|λij|) (4.4)
where λ is the collection of all λ’s in Λ and Ca,b is the normalizing constant.
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The prior for σ2 is pi(σ2) ∝ 1/σ2
4.3.2 Posterior Distribution
The likelihood function from (4.1) is:
L(β,λ;X,y) = (2piσ2)−n/2 exp{−(y −Xβ)
′(y −Xβ)
2σ2
} (4.5)
After multiplying the priors of σ2, β and λ, the joint posterior distribution is:
pi(σ2,β,λ|X,y) ∝ (4.6)
σ−(n+p+2){
∏
i
λ
−3/2
ii
∏
j<i
|λij|−3/2} exp{−(y −Xβ)
′(y −Xβ)
2σ2
}
× exp{− r
2σ2
β′Λβ − a
2
2
∑
i
λ−1ii −
b2
2
∑
j<i
|λij|−1}
The full conditional posterior distribution for β is followed a normal distribution
as:
β|σ2,λ,X,Y ∼ Np((X ′X + rΛ)−1X ′y˜, σ2(X ′X + rΛ)−1) (4.7)
Integrating out β from (4.6), they get the posterior distribution of σ2:
σ2|λ,X,y ∼ Inv −Gamma(n/2,y′(In −X(X ′X + rΛ)−1X ′)y/2) (4.8)
The conditional posterior distribution for λ does not have a closed form, but it
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can be obtained as:
pi(λ|β, σ2,X,y) ∝
∏
i
λ
−3/2
ii
∏
j<i
|λij|−3/2 exp{− r
2σ2
β′Λβ− a
2
2
∑
i
λ−1ii −
b2
2
∑
i<j
|λij|−1}
(4.9)
4.3.3 MCMC
In order to sample from (4.9), the parameter space is augmented. Let ηij = |λij| and
cij = sign(λij). And cij can be either +1 or -1 here. Let pij be the probability that
cij = +1, and cij follows Bernoulli distribution:
pi(cij|β, σ2,X,y) = pij (4.10)
where pij = [1 + exp{−rb(|βi − βj|+ |βi + βj|)/2σ}]−1
η can be divided into 2 cases, ηii and ηij.
ηii|β, σ2,X,y ∼ Inv −N(aσ|
√
rβi|−1, a2) (4.11)
and
ηij|β, σ2,X,y ∼ Inv −N(bσ|
√
r(βi + cijβj)|−1, b2) (4.12)
The Gibbs sampler is developed as follow:
• Update σ2 from (4.6).
• Update β from (4.7).
• Update c from (4.10).
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• Update η from (4.11) and (4.12). Set λii = ηii and λij = cijηij
4.3.4 Choice for Hyperparameters
Conditioned on c and β, the hyperparameters r, a, and b are:
r|a, b, c,β ∼ Gamma(p
2
+ hr,
∑
i β
2
i
2σ2
+
a
∑
i |βi|
2σ
+
b
∑
i<j |βi + cijβj|
2σ
) (4.13)
a|r, b, c,β ∼ exp(ga + r
∑
i |βi|
2σ
) (4.14)
b|r, a, c,β ∼ exp(ga +
r
∑
i<j |βi + cijβj|
2σ
) (4.15)
In order to get a relatively flat prior, ga, hb and gb should be small. In each
iteration, these hyperparameters are updated by drawing samples from their full
conditional distributions.
4.4 Software
RCPP package, BVSG.cpp, is available to preform Bayesian Graph Laplacian Model.
ga, hb and gb should be set to small values. The function BVSGR can be used to
find out the posterior of β’s and the correlation matrix between them. The function
myheatmap can be used to show the correlation matrix graphically. Beside heat maps,
it also includes the dependence structure among the β’s.
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4.5 Application
The data we use are from the Michigan prostate cancer study [Dhanasekaran et al.,
2001]. In order to screen prostate cancer, Prostate Specific antigen (PSA) is used as
a biomarker. [Dhanasekaran et al., 2001] shows that some of the genetic pathways
relative to non-cancerous tissue seemed to be impaired in the prostate cancer, and
[Tang et al., 2013] indicates 16 KEGG pathways might be related to prostate cancer.
Due to the complexity of the gene interaction within a pathway, we use the Bayesian
Graph Laplacian Model to model the pathway effect.
There are 101 patients with 7103 gene microarray expression in the data set. We
select 77 patients who had preoperative prostate-specific antigen (PSA) information
and 368 genes from 16 KEGG pathways related to prostate cancer in our study. We
applied [Liu et al., 2014] method to the prostate cancer data. For each pathway,
preoperative PSA is the response variable and the genes are independent variables.
We used 20,000 iterations with burnin 10,000 iterations. If the absolution values
of the coefficients are greater than 2 or the correlation between two genes are great
than 0.2 or less than -0.2, we consider those genes are important. Table 4.1 and 4.2
summarized those important genes. Based on literature research, * marked genes are
related to cancer and § marked genes are related to prostate cancer. For example, one
of the critical determinants for the development and progression of human prostate
cancers is the androgen receptor (AR). In prostate cancer cells, AR-mediated gene
expression is suppressed by inhibition of PI3K activity, and [Zhu et al., 2008] shows
PIK3R1 (hsa:5295) is one of the primary genes they are interested in after the treat-
ment with PI3K inhibitors. Figure 4.1 to 4.32 show the heat map and dependent
structure among the genes in these 16 pathways. Graph Laplacian shows us what
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genes might be related and how strong their relations are. For instance, Figure 4.5
shows the heat map of mTOR signaling pathway. The tiles off the diagonal show the
correlation between two genes. The darker the color is, the stronger the correlation
is. If the absolute value of the correlation between two genes are more than 0.2,
the two genes are assumed to be related. Figure 4.6 shows the dependent structure
among the genes. The number indicates the order of the genes in mTOR signaling
pathway. For example, 4 denotes hsa:9706 and 12 denotes hsa:7248. Those two genes
are connected with a blue line, which indicates that they are related. The thicker the
blue line is, the stronger the two genes are related.
The information of how strong the genes are related is not available in the KEGG
data, let alone the interaction between genes might be different among different dis-
eases. By using the graph Laplacian model, we can find out underlie relationship
between the genes in response to prostate cancer or other diseases.
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Important Important Genes(Entrez) Important Genes
Pathways |β| > 2 correlation great than 0.2
MAPK signaling pathway 3845 9261 1386 5062∗ 10746§ 9479§ 5320 6654∗ 776 3925
5530 7157∗ 4217§ 10746§ 4609∗
ErbB signaling pathway 6198∗ 5062∗ 6777 3725∗ 5291∗ 5894∗ 3725∗ 5062∗ 5295§ 5894∗
673 3845
mTOR signaling pathway 51719∗ 673 9706 6194∗ 6198∗ 7422∗ 51719∗ 6198∗ 6194∗ 9706
7248 6195∗ 6197§ 5291∗ 5295§ 5296 6199∗ 3091§ 5291∗ 7422∗
7249 7248 6195∗ 6197§
5290∗ 5295§ 3479
Wnt signaling pathway 5530 8322∗ 8324 5881∗ 595 3725∗ 5332∗ 3725∗ 4316 4609∗
1488 6885∗ 5515 5516 1454 8454∗ 6424
Axon guidance 2773 7852∗ 5881∗ 4775 5530 5532 5881∗ 5058∗ 64221 1969∗
5533 3983∗ 2534 5747∗ 998∗ 9475 1948 5530 9475 4690
5058∗ 5062∗ 387§ 3688 4690 64221 1949∗ 4233∗ 6387∗ 2932
1969∗ 1947∗ 2048∗ 2050 23365§ 3845
5362 6405∗ 10500 9901 6387∗
Focal adhesion 5728∗ 5747∗ 1292 3909 7058∗ 7060 10398 1281 5290∗ 3480§
858 7422∗ 5062∗ 5295§ 7414 2335 7058∗
3479 3725∗
Long-term potentiation 5530 6195∗ 5566 10411 5894∗ 673 5578§ 4659 5894∗ 5908
3845 5502 1387 5530 5906 5330∗
5332∗
Neurotrophin signaling pathway 5291∗ 3845 673 4217§ 3667 9261 5295§ 4217§ 3725∗ 397
998
Insulin signaling pathway 7248 51763 5792∗ 5565 5573 31 2194 5567 5257 8835∗
6194∗ 2308 3845 6464 6198∗ 7249 6198∗ 31 673 5290∗
673 5106∗ 10891 5291∗ 2932 5584
5590 10211
Pathways in cancer 3908 3909 5728∗ 8322∗ 8324 3815 3688 999∗ 3685∗ 3480§
2261 7175 7184 2932 4193∗ 6772 5290∗ 5295§ 2335 3815
673 5979 2353 54583 4436 1488 3725∗ 2950§ 5602∗ 7175
2950§ 5915 3728 5371 8554§ 9063 3479 6772 3091§ 4436
5925∗ 329 9618 7422∗ 1436 2247 7042 5743∗ 329
* marked indicates the gene related to cancer
§ marked indicates the gene related to prostate cancer
Table 4.1: Summary of the important genes in 16 pathways (1)
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Important Important Genes(Entrez) Important Genes
Pathways |β| > 2 correlation great than 0.2
Colorectal cancer 8322∗ 8324 5291∗ 4436 3845 5295§ 3725∗
Endometrial cancer 3845 2932 842 6934 83439 5728∗ 6654∗ 5295§
4609∗ 5291∗ 5295§ 5894∗ 673
Glioma 1956∗ 5156 6464 5894∗ 673 5290∗ 3479 6464 6654∗ 1956∗
5291∗ 207 5728∗ 1019∗ 1021 5925 5154 5291∗ 3480§ 5295§
1869§ 5335 3845 1021 5335 3845
Prostate cancer 5728∗ 2308 3845 5925∗ 2932 7184∗ 1956∗ 3480§ 3479
5291∗ 673
Chronic myeloid leukemia 7042 3066∗ 1488 6777 4792 6464 3066∗ 5291∗ 5290∗ 5295§
5925∗ 5291∗ 5296 5894∗ 673 3845 3845
Non-small cell lung cancer 842 5291∗ 5296 1019∗ 1021 1869§ 5578§ 842 5291∗ 1021
3845 1956∗ 6789∗ 2064∗ 5925∗ 5915 5295§ 6654∗ 207 595
369 5894∗ 673 3845 1956∗ 6655
* marked indicates the gene related to cancer
§ marked indicates the gene related to prostate cancer
Table 4.2: Summary of the important genes in 16 pathways (2)
4.6 Discussion
In this Chapter, we apply the Bayesian Graph Laplacian Model to analyze the gene
network and interaction in response to prostate cancer. The table 4.1 and 4.2 shows
the model findings. According to current research literature, we notice that the im-
portant genes picked up by interaction relationship are more likely related to prostate
cancer or cancer than those picked up by larger absolute value of β’s. This might be
because cancer is caused by the interaction of a set of genes rather than individual
genes. In genetic study, the gene relationship is not available sometimes, and often
incomplete. It is also possible that genes relate differently in response to different dis-
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Figure 4.1: Heat Map of MAPK
signaling pathway
Figure 4.2: Dependence Structure
among Genes of MAPK signaling
pathway
Figure 4.3: Heat Map of ErbB sig-
naling pathway
Figure 4.4: Dependence Structure
among Genes of ErbB signaling
pathway
Figure 4.5: Heat Map of mTOR
signaling pathway
Figure 4.6: Dependence Structure
among Genes of mTOR signaling
pathway
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Figure 4.7: Heat Map of Wnt sig-
naling pathway
Figure 4.8: Dependence Structure
among Genes of Wnt signaling
pathway
Figure 4.9: Heat Map of Axon
guidance
Figure 4.10: Dependence Struc-
ture among Genes of Axon guid-
ance
Figure 4.11: Heat Map of Focal
adhesion
Figure 4.12: Dependence Struc-
ture among Genes of Focal adhe-
sion
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Figure 4.13: Heat Map of Long-
term potentiation
Figure 4.14: Dependence Struc-
ture among Genes of Long-term
potentiation
Figure 4.15: Heat Map of Neu-
rotrophin signaling pathway
Figure 4.16: Dependence Struc-
ture among Genes of Neu-
rotrophin signaling pathway
Figure 4.17: Heat Map of Insulin
signaling pathway
Figure 4.18: Dependence Struc-
ture among Genes of Insulin sig-
naling pathway
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Figure 4.19: Heat Map of Path-
ways in cancer
Figure 4.20: Dependence Struc-
ture among Genes of Pathways in
cancer
Figure 4.21: Heat Map of Colorec-
tal cancer
Figure 4.22: Dependence Struc-
ture among Genes of Colorectal
cancer
Figure 4.23: Heat Map of En-
dometrial cancer
Figure 4.24: Dependence Struc-
ture among Genes of Endometrial
cancer
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Figure 4.25: Heat Map of Glioma
Figure 4.26: Dependence Struc-
ture among Genes of Glioma
Figure 4.27: Heat Map of Prostate
cancer
Figure 4.28: Dependence Struc-
ture among Genes of Prostate can-
cer
Figure 4.29: Heat Map of Chronic
myeloid leukemia
Figure 4.30: Dependence Struc-
ture among Genes of Chronic
myeloid leukemia
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Figure 4.31: Heat Map of Non-
small cell lung cancer
Figure 4.32: Dependence Struc-
ture among Genes of Non-small
cell lung cancer
eases. One of the advantages of Bayesian Graph Laplacian Model is that a completely
known dependence structure is not needed.
[Liu et al., 2014] compares the performance of Bayesian Graph Laplacian Model
with that of Lasso, EN, OSCAR, Bayesian Lasso and Bayesian Elastic Net in 5
different scenario simulation studies. Bayesian Graph Laplacian Model preform best
in four scenarios and second to the best in one scenario.
[Liu et al., 2014] proposed method can be used for one pathway each time, with
the information that we already know the potential important pathways. Some of the
diseases, especially cancers, might be caused by the multiplied pathways interacting
with each other. It is worthwhile to extend the method to pin point important
pathways among all potential disease related pathways. We could possibly find out
the interaction between pathways through the interaction among genes, because one
disease related gene can be in multiple different pathways.
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Chapter 5
Future Study
5.1 Multiple Pathways Simultaneous Analysis and
Pathways Selections
When we analyze the gene expression data in Chapter 4, one of the limitations of
Bayesian Graph Laplacian Model is that we can only analyze each pathway individ-
ually. However, in disease research, especially in cancer, it is important to consider
the interaction between pathways, as some of the diseases are the result of several
pathways interactions. According to the current biology research, there are more
than 200 pathways information available ,but most of the pathways are unrelated to
the diseases, so it is important for us to select possible disease related pathways. We
would like to extend the Graph Laplacian method with pathway selection.
First consider a linear regression function,
yi = x
(1)T
i β1 + x
(2)T
i β2 + · · ·+ x(L)Ti βL + ei, (5.1)
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where ei ∼ N(0, σ2), yi is continuous variables for ith observation, i = 1, · · · , n, x(l)i
is the microarray expression data for lth pathway, and l = 1, · · · , L. In this section yi
is continuous variable , similar to preoperative PSA. x
(l)T
i βl is the lth pathway effect
and we assume additive effect on the response variable.
Similar to chapter 2, we assume the regression coefficients arise from a scale mix-
ture of a point mass of 0 and a normal distribution, so we have:
βl|φl = φlNpl(0,
σ2
rl
Λ−1l ) + (1− φl)I(0), (5.2)
where φl is the pathway selection indicator for lth pathway,
φl = 1 when pathway is l selected in the model
φl = 0 otherwise
(5.3)
and it follows Bernoulli distribution:
φl = ω
φl
l (1− ωl)φl (5.4)
And σ2l ∼ IG(al, bl), a, b, rl ≥ 0 and ωl are hyperparameters. Moreover, Λ−1l is
the inverse of the graph Laplacian matrix, and it is as follows:
Λl =

1 + λ
(l)
11 +
∑
j 6=1 |λ(l)1j | λ(l)12 · · · λ(l)1p
λ
(l)
21 1 + λ
(l)
22 +
∑
j 6=2 |λ(l)2j | · · · λ(l)2p
...
...
. . .
...
λ
(l)
p1 · · · · · · 1 + λ(l)pp +
∑
j 6=p |λ(l)pj |

(5.5)
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where λ
(l)
ij = λ
(l)
ji and λ
(l)
ii > 0 The prior for λ
(l) is:
pi(λ(l)) ∝ Ca,b|Λl|−1/2
p∏
i=1
(λ
(l)
ii )
−3/2 exp(− a
2
2λ
(l)
ii
)I(λ
(l)
ii > 0)
(l)∏
j<i
|λij|−3/2 exp(− b
2
2|λ(l)ij |
)
(5.6)
The prior distribution for β’s will shrink the β’s values close to 0 when those β’s
and corresponding pathways are not important. In such way, we can select pathways.
5.2 Survival Time as Response Variable
In disease related research, it is common to use survival time as the response variable.
We would like to extend the Graph Laplacian method with right censored response.
We replace the original regression model with Accelerated Failure Time (AFT) mod-
els. AFT models assume multiplicative effect of the pathway effect on the survival
time:
log(ti) = x
(1)T
i β1 + x
(2)T
i β2 + · · ·+ x(L)Ti βL + ei, (5.7)
where we have the survival time ti for subject i. Let ci be the censoring time indepen-
dent of ti. Let δi = I{ti ≤ ci} to be censored indicator function and t∗i = min(ti, ci).
We impute the censored data by using the [Tanner and Wong, 1987] data augmenta-
tion approach. Let Y = (Y1, Y2, · · · , Yn)′, and yi is the augmented data as,
Yi = log(t
∗
i ) if δi = 1
Yi > log(t
∗
i ) if δi = 0
(5.8)
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Assuming the error term is iid following standard normal distribution, the model
(5.7) becomes:
Yi = x
(1)T
i β1 + x
(2)T
i β2 + · · ·+ x(L)Ti βL + ei, ei iid∼ N(0, σ2) (5.9)
5.3 Binary Response Variable
In medical research, sometimes, researchers are interested in classifying or discriminat-
ing different diseases or cancers. In this case, the response variables are dichotomous
or categorical. So we would like to extend the Graph Laplacian method with binary
response and multinomial response to analyze those research questions.
Suppose yi is binary random variables, where i = 1, · · · , n, and yi = 1 or yi = 0.
We use the data augmentation method introduced by [Tanner and Wong, 1987]. Let
z1, · · · , zn be n latent variables, and zi are independent N(XTi B, 1), where Xi =
c((x
(1)
i )
T , · · · , (x(L)i )T )T and B = c(β1, · · · ,βL). Let
yi = 1 if zi > 0
yi = 0 if z1 ≤ 0
(5.10)
As a result, yi follows Bernoulli distribution with pi = P (y1 = 1) = Φ(X
T
i B). The
prior of βl is the same as (5.2).
For the multinomial response, if the responses are ordinal variables, we suppose
yi takes K ordered categories. Let pik = P (yi = k) and cumulative probabilities
ηik =
∑K
k=1 pik, where k = 1, · · · , K − 1. Following [McCullagh, 1980], we have
ηik = Φ(γk −XTi B). Similarly, if zi are independent N(XTi B, 1), let yi = k, when
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we have γk−1 < zi ≤ γk.
Lastly, if the responses are nominal variables. [Aitchison and Bennett, 1970]
applied Gibbs sampling approach to multinomial probit model. In our specific model
setting, let zi = zi1, · · · , ziK , where i = 1, · · · , n and K > 2, we have:
zik = X
T
ikBk + eik, (5.11)
where ei = (ei1, · · · , eiK). Pathway selections are different in different diseases, so
disease k has its own set of genes Xik and corresponding βk. Disease k is observed if
zik > zim for all k 6= m.
We believe with these three extensions, Bayesian Graph Laplacian Model can be
used in most of biological or medical research data.
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